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Abstract 
Homeostasis is a dynamic equilibrium fundamental for a healthy system. A major 
challenge to homeostasis is environmental stress to which the organism reacts with the 
stress response. The hypothalamic-pituitary-adrenal (HPA) axis is the main regulator of the 
stress response that, upon activation, leads to the release of glucocorticoids (GCs). GCs are 
steroid hormones that exert their function via glucocorticoid receptors (GR). They trigger 
on one hand the appropriate stress response in the periphery, and, on the other, inhibit the 
HPA axis itself via negative feedback to restore homeostasis. FK506-binding protein 51 
(FKBP51) is a co-chaperone able to modulate the GR, and therefore the HPA axis. 
Furthermore the expression of FKBP5, the gene coding for FKBP51, is induced by GR 
activation. In the last decade, increasing evidence has unveiled additional roles of FKBP51 
in the regulation of several cellular pathways and functions that are independent from its 
inhibitory role on GR. Among these, FKBP51 has been shown to link stress signaling to 
macroautophagy, a lytic type of autophagy pathway. Autophagy represents one of the main 
mechanisms regulating cellular homeostasis and response to stress. For this reason, in the 
first part of this doctoral thesis, the role of GR-mediated stress was investigated on two 
further autophagic pathways: 1) the chaperone-mediated autophagy (CMA), a selective 
type of lytic autophagy, and 2) the secretory autophagy, an unconventional secretory 
mechanism regulated by autophagy-related proteins and found to be involved in 
extracellular signaling of immune response. For this aim, an in vitro approach was adopted 
using human and murine cell lines that were treated with dexamethasone (Dex), a synthetic 
GR agonist.  
For the first pathway, biochemical assays indicated that Dex-induced GR activation 
enhances CMA-mediated degradation of known CMA target proteins and that this process 
is dependent on FKBP51. Furthermore, the underlying molecular mechanism could be 
revealed by co-immunoprecipitation that displayed the co-localization of FKBP51, AKT and 
PHLPP on lysosomes. With a SILAC-based proteomics analysis, the proteome-wide effect of 
Dex-induced CMA could be observed and novel CMA targets were identified. 
For the second pathway, interactome and co-immunoprecipitation analyses revealed the 
involvement of FKBP51 in the SNARE complex assembly essential for secretory autophagy. 
Furthermore, treatment with Dex lead to a strengthened interaction between the SNARE 
proteins and FKBP51, and to an increased secretion of IL1B, a well characterized cargo of 
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secretory autophagy, as observed with in vitro ELISA experiments and in vivo hippocampal 
microdialyses. A global effect of Dex-induced secretory autophagy was finally observed with 
a secretome analysis. 
The second part of my doctoral thesis focused on FKBP5/51 transcription variants and 
protein isoforms. In fact, despite its involvement in many cellular functions and disorders, 
very little is known about its four transcription variants and two isoforms. Thus, expression 
and degradation dynamics of FKBP51 isoforms and their differential functions in known 
molecular pathways were analyzed. 
Overall this study highlighted FKBP51 as crucial mediator of the stress response on two 
autophagic pathways, which might contribute to the regulation of cell and protein 
homeostasis. Furthermore, this regulatory mechanism might underlie the link of stress to 
immune and psychiatric disorders. 
 
 vi 
 
Zusammenfassung 
Homöostase, die Aufrechterhaltung physiologischer Funktionen in einem dynamischen 
Gleichgewicht, ist Voraussetzung für ein gesundes biologisches System. Eine große 
Herausforderung für die Homöostase ist Umweltstress. Der Organismus reagiert mit einer 
Stressreaktion. Hauptregulator der Stressreaktion ist die Hypothalamus-Hypophysen-
Nebennieren (HPA) -Achse, die bei Aktivierung zur Freisetzung von Steroidhormonen, den 
Glukokortikoiden (GCs) führt. Glukokortikoide aktivieren Glukokortikoidrezeptoren (GRs), 
die einerseits die angemessene Stressreaktion in der Peripherie auslösen und andererseits 
die HPA-Achse selbst durch negatives Feedback hemmen, um die Homöostase 
wiederherzustellen. Das FK506-binding protein 51 (FKBP51) ist ein Co-Chaperon, das den 
GR und damit die HPA-Achse modulieren kann. Darüber hinaus wird die Expression von 
FKBP5, dem für FKBP51 kodierenden Gen, durch GR-Aktivierung induziert. Zunehmende 
Erkenntnisse in den letzten zehn Jahren weisen auf weitere Rollen von FKBP51 bei der 
Regulation mehrerer zellulärer Signalwege und Funktionen, die unabhängig von seiner 
inhibitorischen Rolle auf den GR sind. So wurde zum Beispiel gezeigt, dass FKBP51 das 
Stresssignal auf Makroautophagie vermittelt. Makroautophagie stellt eine Form der 
Autophagie dar, einer der Hauptmechanismen zur Regulierung der zellulären Homöostase 
und der Reaktion auf Stress. Daher wurde im ersten Teil der vorliegenden Arbeit die 
Wirkung des GR-vermittelten Stresses durch FKBP51 auf zwei weitere Autophagie-
Signalwege untersucht. 1. Auf die Chaperon-vermittelte Autophagie (CMA), eine selektive 
Art der lytischen Autophagie und 2. Auf die sekretorische Autophagie, einen 
unkonventionellen sekretorischen Mechanismus, der an der extrazellulären 
Signalübertragung der Immunantwort beteiligt ist. Es wurde ein in vitro-Ansatz mit 
menschlichen und murinen Zelllinien verwendet, die mit Dexamethason, einem 
synthetischen GR-Agonisten behandelt wurden.  
Für den ersten Signalweg zeigten biochemische Assays, dass Dexamethason-induzierte 
GR-Aktivierung den CMA-vermittelten Abbau bekannter CMA-Zielproteine verstärkt und 
dass dieser Prozess durch FKBP51 vermittelt wird. Darüber hinaus konnte der zugrunde 
liegende molekulare Mechanismus durch Co-Immunopräzipitation aufgedeckt werden, die 
eine Co-Lokalisierung von FKBP51, AKT und PHLPP auf Lysosomen ergab. Mit einer SILAC-
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basierten Proteomics-Analyse konnte der proteomweite Effekt von Dexamethason-
induziertem CMA beobachtet und neuartige CMA-Ziele gefunden werden. 
Für den zweiten Signalweg zeigten Interaktom- und Co-Immunpräzipitationsanalysen, 
dass FKBP51 an der SNARE-Komplexanordnung sowohl beteiligt, als auch Voraussetzung für 
dessen Bildung ist, die wiederum für die sekretorische Autophagie essentiell ist. Die 
Behandlung mit Dexamethason führte nicht nur zu einer verstärkten Wechselwirkung 
zwischen den SNARE-Proteinen und FKBP51, sondern auch zu einer erhöhten Sekretion von 
IL1B. Dies konnte anhand von ELISA-Experimenten in vitro und Mikrodialysen in vivo 
charakterisiert werden. Ein globaler Effekt der Dexamethason-induzierten sekretorischen 
Autophagie wurde schließlich mit einer Sekretomanalyse beobachtet. 
Der zweite Teil meiner Doktorarbeit befasst sich mit FKBP51-Transkriptionsvarianten 
und Isoformen des Proteins. Obwohl es eines der am meisten untersuchten Gene im 
Bereich der Psychiatrie darstellt und an zahlreichen zellulären Funktionen beteiligt ist, ist 
nur wenig über seine vier Transkriptionsvarianten und zwei Isoformen bekannt. Daher 
wurden die Expressions- und Degradationsdynamik der Isoformen und ihre 
unterschiedlichen Funktionen auf FKBP51 regulierte Signalwege charakterisiert. 
Insgesamt verdeutlicht die vorliegende Arbeit die entscheidende Rolle von FKBP51 als 
Mediator der GR-vermittelten Stressreaktion auf zwei Signalwege der Autophagie, die CMA 
und die sekretorische Autophagie, und damit möglicherweise dessen zentrale Bedeutung 
im Regulationsmechanismus der Proteinhomöostase bei der Stressreaktion. Weiterhin 
markieren diese Mechanismen mögliche molekulare Grundlagen von stressbedingten 
immunologischen und psychiatrischen Störungen. 
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1. Introduction 
 
1.1. Homeostasis and stress  
All living organisms strive to maintain homeostasis, a dynamic equilibrium fundamental 
for a healthy system. The concept of homeostasis was first defined by Walter Bradford 
Cannon in the beginning of the 19th century, who wrote: “the blood and other fluids 
surrounding cells constitute the internal environment with which occur direct exchanges of 
each cell, and this must always be kept with parameters suitable for cell function, regardless 
of changes that may be occurring in the external environment.” (Cannon, 1929). Such 
changes in the external environment can be real or potential threats defined as stressors, 
and the pursuit to maintain homeostasis as described by Cannon triggers a response, called 
stress response. In the last decades, research unraveled the complex mechanism regulating 
the stress response, starting by the definition of a stress system that comprises various brain 
structures. These structures integrate different stressors and activate appropriate stress 
responses that, through physiological and behavioral mechanisms, are able to restore 
homeostasis and promote adaptation (Joëls and Baram, 2009; de Kloet et al., 2005). 
Additionally, the concept of homeostasis itself has evolved into allostasis, allostatic load and 
allostatic overload, to define more precisely the “equilibrium” needed in different 
circumstances. Homeostasis is hence set at different points in dependence of the stress 
load (Dallman, 2003). Upon perception of a stressor, the stress hormone system is 
activated. It involves different structures of the central nervous system (CNS) that 
communicate within the CNS and to the periphery. Two phases of the stress response can 
be distinguished: an initial immediate and fast systemic response carried out by the 
sympathetic adrenomedullar system (SAM) that leads to an activation of short-lasting 
responses such as increased alertness, vigilance and appraisal, typical of the “fight-or-flight” 
response (Cannon, 1915), and a slower hormonal response. This slower mechanism involves 
the hypothalamic pituitary adrenal (HPA) axis and results in the release of glucocorticoids 
(GCs), which cause an amplified and protracted long-lasting response. In this work I will 
focus on this latter stress response mediated by the HPA axis, and, unless otherwise 
specified, I will define as stress every input that leads to activation of the GC receptors (GR; 
described further on).  
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1.1.1. The HPA axis 
In the presence of a stressor, the HPA axis is activated. Brain regions receiving stimuli 
affecting homeostasis activate the initiators of the axis: the hypophysiotropic neurons, 
localized in the paraventricular nucleus (PVN) of the hypothalamus. These neurons 
synthesize and secrete the corticotropin-releasing hormone (CRH), the first 
neuromodulator and crucial regulator of the axis. Through the hypophyseal portal vessels, 
CRH is transported to the anterior pituitary gland. Here it binds to the CRH receptor 1 
(CRHR1), stimulating the release of the adrenocorticotropic hormone (ACTH) out of the CNS 
into systemic circulation. The principal target of ACTH is the melanocortin type 2 receptor 
(MC2-R) on the adrenal cortex. The activation of these receptors promotes the synthesis of 
GCs, the end effector of the axis, and their release in the bloodstream (Simpson et al., 1988). 
The most abundant circulating GC hormone in humans is cortisol (CORT; corticosterone in 
mice). At basal levels, most of the circulating CORT (>90%) is bound to carrier proteins, in 
particular to corticosteroid binding globulin (CBG), to which it has the highest affinity. The 
bioavailability (unbound CORT) increases upon stress-induced increase of CORT levels, as 
the CBG buffer capacity reaches saturation. Its lipophilic nature allows CORT to pass the 
blood brain barrier (BBB) and cell membranes without needing further carriers, virtually 
reaching every cell in the body. Its activity, however, is exerted only in cells expressing 
specific nuclear receptors: the glucocorticoid- (GR) and the mineralocorticoid receptor 
(MR). MRs are occupied to a much greater extent than GR due to their 10 fold increased 
affinity to CORT (Reul and de Kloet, 1985), resulting in an almost saturation of the MR at 
basal levels of cortisol. On the contrary, GRs are significantly occupied only during an 
increase of CORT levels during peaks of the circadian cycle or with acute stress (Reul and de 
Kloet, 1985; Spencer et al., 1993), assuming a more dynamic role in the stress response. 
The differential function of the two GC receptors is also dependent on their distribution 
pattern within different tissues. In the brain, MRs are expressed predominantly in limbic 
areas such as hippocampus, lateral septum and central amygdala, while GR is ubiquitously 
expressed (Mifsud and Reul, 2018).  Activation of MRs and GRs by GCs leads to the activation 
of an adaptive stress response that involves many diverse physiological processes including 
immune, cognitive and metabolic ones. These cause changes in physiology and behavior 
directed to counteract the stress stimulus. In addition to generating an adequate stress 
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response, activation of GRs induces a rapid repression of genes that encode for mediators 
of the HPA axis, such as CRH and ACTH (Russell et al., 2010; Watts, 2005). This negative 
feedback is a regulatory mechanism, crucial for terminating the stress response and 
restoring the correct homeostasis after the end of a threat (fig. I a). In fact, an imbalance 
between activation and inhibition of the stress response can lead to the development of 
pathological states. Disruption of normal HPA function, termed allostatic load, is a hallmark 
of somatic and neuropsychiatric diseases, such as metabolic dysfunction, major depression 
disorder (MDD), anxiety and posttraumatic stress disorder (PTSD) (Gotlib et al., 2008; de 
Kloet et al., 2006; Macfarlane et al., 2008; Pariante and Lightman, 2008; Rosmond, 2003; 
Shea et al., 2005). A mechanism that increases the risk for disrupting the HPA function and 
developing psychiatric disorders is the exposure to early life adversities. In fact, the stress 
response is shaped by genetics and environment; hence early life phases are particularly 
critical because the brain is more vulnerable to external stimuli. Early life adversities have 
been found to cause a long-term impact on the circuitry responsible for emotional and 
cognitive functions, and are found to be associated with increased vulnerability to develop 
psychiatric disorders later in life (Chrousos, 2009; Heim and Nemeroff, 2002; Juruena, 2014; 
Krugers et al., 2017; Lippmann et al., 2007; Lucassen et al., 2013; Lupien et al., 2009).  
At the cellular level, in the absence of ligand, GR and MR are primarily localized in the 
cytoplasm in an inactive state as part of a multiprotein complex that includes the chaperone 
heat-shock protein 90 (HSP90) and a number of co-chaperones and molecules. The co-
chaperones define the maturation state of the complex that determines the binding 
capability of the GR and MR. In the  mature state, these nuclear receptors (GR and MR) are 
bound to HSP90 together with the co-chaperones Cyclophilin 40 (Cyp40), Protein 
Phosphatase 5 (PP5), FK506 binding protein 51 (FKBP51) and the co-chaperone molecule 
p23 (Sanchez, 2012). However, upon binding of CORT, FKBP51 is replaced by its closest 
homologue FKBP52. FKBP52, unlike FKBP51, promotes nuclear receptors translocation into 
the nucleus through binding to the dynamitin subunit of the dynactin transport machinery 
(Galigniana et al., 2004; Harrell et al., 2004; Wochnik et al., 2005). This switch allows the 
translocation of GR and MR into the nucleus where they homo- and heterodimerize and 
bind to a palindromic 15 DNA base pair consensus sequence, known as GC response 
element (GRE), enhancing or repressing the transcription of numerous GC-responsive genes 
(Mifsud and Reul, 2016; Nicolaides et al., 2014). FKBP51 and FKBP52 exert, therefore, 
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respectively an inhibiting and activating function on the GR and MR. Interestingly, the gene 
coding for FKBP51, FKBP5, is one of the GC-responsive genes, whose expression is enhanced 
upon GR and MR activation (Jääskeläinen et al., 2011). This regulation results in an ultra-
short negative feedback on the receptors at the cellular level, and, by extension, on the HPA 
axis (Denny et al., 2000; Zannas and Binder, 2014). Given the different dynamics of GR and 
MR, in this work I will only focus on the GR, assuming a lesser impact of the MR in the 
analyzed processes. 
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Figure I – Regulation of stress response. a) HPA axis: an environmental stressor perceived by 
different brain structures stimulates hypophysiotropic neurons in the PVN leading to the secretion 
of CRH into the hypophyseal portal vessels. These transport CRH to its receptor in the pituitary 
gland where secretion of ACTH is triggered. ACTH exits the CNS and binds MC2-R on the adrenal 
cortex, leading to the secretion of GCs. GCs bind to GRs and MRs triggering, on one hand, a stress 
response in the periphery, and on the other exerting a negative feedback of the HPA axis itself. b) 
At the cellular level, inactive GR is part of a multi-protein complex including HSP90 and FKBP51, 
localized in the cytoplasm. Upon CORT binding, FKBP51 is replaced by FKBP52 that allows 
translocation into the nucleus and activation of its transcription function. Among the genes 
regulated by GR is FKBP5 itself, which expression is increased, leading to an ultra-short negative 
feedback of GR activity. 
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1.2. FKBP51: a co-chaperone for stress modulation 
FKBP51 is an immunophilin, member of the FK506 binding proteins (FKBPs) (Schreiber, 
1991; Trandinh et al., 1992). At least 15 FKBPs have been identified in humans and the suffix 
designates the approximate molecular mass of these proteins (Somarelli et al., 2008) that 
are ubiquitously found in almost all organisms and subcellular compartments (Romano et 
al., 2011). FKBP51´s inhibitory effect on GR was initially discovered in New World monkeys, 
which have very high circulating GC levels but do not present any associated 
symptomatology that would occur for example in humans. The explanation to this was given 
by the concurrent inherently high levels of FKBP51 that confer GR resistance (Scammell et 
al., 2001). As mentioned before, the gene coding for FKBP51, FKBP5, is regulated by GR 
itself, leading to an ultra-short negative feedback of the GR and, by extension, of the HPA 
axis (fig. I b). As a modulator of the stress response, it appears clear that a correct regulation 
of FKBP5 expression levels are of crucial importance.  
 
1.2.1. Genetic and epigenetic regulatory mechanisms 
The transcription of FKBP5 is mediated via GREs that are distributed in the regions from 
upstream of the promoter to introns 2, 5 and 7 of the gene (Paakinaho et al., 2010). GRs 
binding to GREs allow the formation of three-dimensional (3D) chromatin loops connecting 
the transcription start site (TSS) and RNA polymerase II (Jääskeläinen et al., 2011). In this 
way, GCs can affect FKBP5’s transcription; gene expression is enhanced compared to the 
basal state (Klengel et al., 2013). At the genetic level, Binder and colleagues discovered an 
association of the intronic single nucleotide polymorphism (SNP) of FKBP5, rs1360780, with 
increased intracellular FKBP51 protein levels. This association was also paralleled with 
increased response to antidepressants and recurrence of depressive episodes. 
Furthermore, only within the TT genotype population, FKBP5 mRNA levels had a significant 
direct correlation with plasma cortisol levels of the individuals (Binder et al., 2004). The 
rs1360780 polymorphism is part of a haplotype, commonly tagged by rs3800373, 
rs9296158, or rs1360780, that spans the entire gene and contains up to 18 SNPs in strong 
linkage disequilibrium in Caucasians. Different studies found this haplotype to be associated 
with increased FKBP5 expression and increased vulnerability to stress-related psychiatric 
disorders (Binder et al., 2008; de Castro-Catala et al., 2017; Zannas et al., 2016). Klengel et 
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al. deciphered the underlying mechanism linking the polymorphism to FKBP5 expression. 
They showed that the previously described 3D chromatin loop is allele-dependent. In fact, 
the sequence containing the T allele forms a TATA box with stronger binding affinity to the 
TATA box binding protein (TBP), compared to the C containing genotype, as revealed by 
chromatin immunoprecipitation experiments (ChIP) (Klengel et al., 2013). Polymorphisms 
can also be a variable in genetically intrinsic patterns of epigenetic modifications both 
indirectly, by influencing the effect of the environment on methylation marks, and directly, 
by disrupting CpG sequences recognized by methyltransferases. For this reason, Klengel and 
colleagues further investigated epigenetic changes of FKBP5 in correlation to its expression 
levels. CpG sites located in the proximity of the functional GRE in intron 7 of FKBP5 were 
analyzed via pyroseqeuncing in bisulfite-treated genomic DNA extracted from peripheral 
blood cells. Demethylation was observed in association with exposure to childhood abuse, 
in rs1360780 T allele carriers (both homo- and heterozygous), but not in individuals with 
the alternate genotype. Furthermore, previous in vivo experiments showing DNA 
demethylation of Fkbp5 in the murine hippocampus, hypothalamus, and peripheral blood 
after systemic exposure to GCs (Lee et al., 2010) support that demethylation in humans 
with early trauma is driven by GR activation. Therefore, environmentally induced DNA 
methylation changes interact with FKBP5 polymorphisms resulting in altered expression. 
Furthermore, FKBP5 expression can also be altered by environmentally-induced histone 
modifications. GR activation has been found to increase histone H3 acetylation and histone 
H3-lysine 4 trimethylation in the FKBP5 gene, enhancing its expression (Paakinaho et al., 
2010). Despite robust findings indicating that GR activation leads to FKBP5 disinhibition and 
demethylation, numerous studies demonstrate that this regulation is dependent on the 
species and the developmental stage. Methylation analyses performed in a human fetal 
hippocampal progenitor cell line stimulated with a synthetic GR agonist dexamethasone 
(Dex) revealed that only when cells were treated in their proliferation and differentiation 
phase, and not once the cells had differentiated, FKBP5 methylation levels were decreased, 
supporting the evidence that regulation of epigenetic changes is specific to developmental 
stages. The same study showed, furthermore, that these demethylations were stable after 
differentiation even if the exposure to GC was terminated (Klengel et al., 2013). However, 
this lasting effect was not seen in a different study conducted by Lee et al., where Fkbp5 
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demethylations observed in different mouse tissues were not maintained upon withdrawal 
of GR agonists (Lee et al., 2010), suggesting a species-specificity.  
Overall these studies provide evidence that FKBP5 expression is regulated by both 
genetic and epigenetic mechanisms and that an increased FKBP5 expression is associated 
with a more dynamic phenotype (increased susceptibility, but also increased response to 
antidepressant; Binder et al. 2004), dependent on the developmental stage and the species.  
 
1.2.2. FKBP5 disinhibition and dysregulation of the stress response 
As a modulator of the stress axis, dysregulation of FKBP5 expression has potentially 
analogous effects to dysregulation of the axis itself. In fact, numerous studies have shown 
correlations between FKBP5 genotype and altered neuroendocrine endophenotypes. The 
rs1360780 haplotype was found to be correlated with suppressed negative feedback of the 
stress axis accompanied by prolonged cortisol release (Ising et al., 2008). Furthermore, 
increased cortisol levels were found in T-allele carriers after Trier social stress test (TSST) in 
correlation with childhood trauma exposure, indicating long-term alterations of 
neuroendocrine regulation associated with FKBP5 genotype (Buchmann et al., 2014). 
Genetic and epigenetic characteristics leading to an increased expression of FKBP5 have 
also been linked to both psychiatric and somatic disorders. 
Psychiatric disorders 
Its central role in the regulation of the stress axis makes FKBP5 the perfect candidate for 
mediating gene-environment interactions underlying mood and anxiety disorders. Klengel 
and colleagues identified the mechanism underlying the correlation between FKBP5 
polymorphisms and its expression levels connected to modulation of the GR response and 
regulation of the stress axis (Klengel et al., 2013). Furthermore, these findings suggest that 
an impaired return to baseline of stress-induced cortisol levels is the basis of an increased 
vulnerability to develop stress-related psychiatric disorders. To date, the strongest 
association so far has been found via clinical studies between FKBP5 disinhibition and PTSD. 
The presence of the T genotype in the rs1360780 polymorphism is predictive of PTSD 
development after childhood trauma (Binder et al., 2008). A recent meta-analysis 
corroborated this association by finding a significant genetic effect of the rs1360780 
haplotype in interaction with trauma exposure on the development of PTSD (Hawn et al., 
2019). A different study analyzing the FKBP5 SNP rs9296158 found that PTSD patients 
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carrying the T allele showed GR super-sensitivity, while hypocortisolism was observed in 
patients with the CC genotype (Mehta et al., 2011). In line with these findings, enhanced 
GR sensitivity was also found in whole blood from PTSD patients in correlation with 
decreased FKBP5 levels (Yehuda et al., 2009). It was also suggested that FKBP5 affects over-
consolidation or impaired extinction of traumatic memories, both characteristics of PTSD 
(Binder, 2009; Gillespie and Ressler, 2005; Pitman and Delahanty, 2005; Rothbaum and 
Davis, 2003). Also, post mortem studies revealed enhanced FKBP5 expression in cortical 
regions of PTSD patients compared to healthy controls (Young et al., 2015). FKBP5 
haplotypes have furthermore been associated with mood disorders such as depression 
(Binder et al., 2004; Höhne et al., 2015) and bipolar disorder (BD) (Willour et al., 2009). 
These results were supported by post mortem brain analyses of cortical and hippocampal 
region samples, where increased FKBP5 mRNA levels were found in subjects with MDD and 
BD (Chen et al., 2013; Darby et al., 2016; Mamdani et al., 2015; Sinclair et al., 2013; Tatro 
et al., 2009). This evidence, together with the data from PTSD subjects, suggests that 
elevated FKBP5 expression in specific brain regions might contribute to psychiatric disorders 
(Matosin et al., 2018).   
Somatic disorders 
Disinhibition of FKBP5 has also been found in correlation with non-psychiatric disorders 
such as Alzheimer´s disease both in post mortem (Braak and Braak, 1991) and animal studies 
(de Calignon et al., 2010, 2012; Lasagna-Reeves et al., 2012; SantaCruz et al., 2005). As 
mentioned previously, dysregulation of the stress axis has been associated with metabolic 
disorders. Indeed, type 2 diabetes, which is considered a stress-related pathophysiology, 
has been associated with the high induction FKBP5 SNPs (Pereira et al., 2014) that also 
correlate with enhanced insulin resistance and elevated serum triglycerides (Fichna et al., 
2018). Hyperexpression of FKBP51 has also been reported in different human cancers such 
as leukemias, gliomas, breast and prostate cancers, and is associated with apoptosis 
resistance and enhanced proliferation in gliomas (Romano et al., 2011). 
 
1.2.3. FKBP51 as a drug target 
Due to its involvement in several disorders, spanning from psychiatric diseases to cancer, 
FKBP51 has attracted interest from different scientific fields as a possible target for drug 
design. An important information deriving from animal studies is that Fkbp5 knock out (KO) 
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mice are viable and do not present pathological alterations that would indicate a possible 
target-related toxicity for FKBP51 drugs (Schmidt et al., 2012). However, in order to 
evaluate the safety and efficacy of FKBP51 as a drug target, its overall expression pattern 
and functions need to be considered. From the literature, FKBP51 would be expected to 
have an effect on GR response, energy metabolism and chronic pain (Balsevich et al., 2017; 
Maiarù et al., 2016, 2018). FKBP5/51 is increasingly being recognized as biomarker for 
tumor progression and is therefore seen as possible target for therapy. A reduction of 
prostate cancer cell proliferation has already been shown as a consequence of FKBP51 
inhibition with the immunosuppressive drug FK506 (Schmidt et al., 2012), and also 
rapamycin, another FKBP ligand, has been reported to have anti-tumor activity (Avellino et 
al., 2005; Romano et al., 2004).  
From a technical point of view, the high similarity to other FKBPs has represented the 
major difficulty so far in the process of ligand design. The first molecule designs were based 
on the known inhibitors rapamycin and FK506; however, these drugs cross-reacted with 
other FKBPs and resulted mainly in an immunosuppressive effect. The search for an FKBP51-
specific, non-immunosuppressive ligand faced a selectivity issue between the homologues 
FKBP51 and FKBP52 (Blackburn and Walkinshaw, 2011).  In 2015 Gaali and colleagues 
developed a series of ligands with a 10’000-fold increased affinity for FKBP51 over FKBP52. 
These ligands are termed Selective Antagonist of FKBP51 by induced fit (SAFit), and include 
two main molecules: 1) SAFit1, with better solubility and slightly better off-target profile, 
preferred for in vitro studies, and 2) SAFit2, with much better pharmacokinetic properties 
and the current gold standard for in vivo studies (Gaali et al., 2015). To date, SAFit ligands 
are the most selective and effective ligands published, nevertheless further optimization is 
required to improve the physicochemical properties in order to be suitably used in the CNS 
(Wager et al., 2010). In fact, SAFit1 and SAFit2 present too high molecular weights (748 and 
803 g/mol, compared to 426 g/mol for 90% of CNS drugs) and too low ligand efficiencies 
(LE = 0.21 and 0.19, compared to 0.37 for 90% of CNS drugs) (Gaali et al., 2016). 
Furthermore, in addition to optimizing the chemical and pharmacokinetic characteristics of 
the drug, increased knowledge on the target itself is necessary to develop an optimal drug. 
A deeper understanding of the numerous functions of FKBP51 are necessary in order to 
achieve a more precise targeting design. 
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1.2.4. Mechanistic studies 
Given the central role of FKBP5 in stress response and its correlation with diverse 
diseases, animal and in vitro approaches were used to deepen the understanding of 
FKBP51´s functions. A study by Scharf et al. in 2011 demonstrated a significant induction of 
Fkbp5 by GCs in a brain region-specific manner (Scharf et al., 2011). The use of Fkbp5 KO 
animals allowed to decipher numerous physiological and behavioral mechanisms. Despite 
Fkbp5 KO mice not displaying major phenotypic differences (under basal conditions) 
compared to their wild type (WT) counterparts, Touma et al., observed significantly 
increased stress-coping behavior after exposure to acute stress (Touma et al., 2011). In 
line with these findings, Hartmann et al. reported prolonged swimming activity of Fkbp5 
KO mice compared to WT in the forced swim test, a paradigm to assess stress coping 
behavior, indicating a higher resilience to stress. Interestingly, the same study reported 
physiological differences between KO and WT mice, independently of the experimental 
condition (stressed vs. non-stressed), observing reduced thymus and adrenal gland 
weights as well as lower body weight in the KO mice.  Furthermore, under chronic stress 
conditions, Fkbp5 KO mice displayed significantly lower CORT levels compared to WT. 
These differences can be connected with the predicted higher GR activity, reduced HPA 
axis activity and increased negative feedback in the KOs compared to the WTs (Hartmann 
et al., 2012). Using tail suspension and forced swim test, O´Leary et al., found that Fkbp5 
KO mice displayed improved stress coping behavior, associated with significantly reduced 
CORT release compared to WT after stress (O’Leary et al., 2011). Analogously, using a 
different strategy, Attwood and colleagues, reported that prevention of Fkbp5 
upregulation, following stress exposure, decreased anxiety-related behavior (Attwood et 
al., 2011). These studies independently demonstrate a direct correlation of Fkbp5 
reduction with antidepressive-like and pro-resilience behaviors. Murine models also 
corroborated the role of Fkbp5 in metabolic disorders. An upregulation of Fkbp5 has been 
reported in mice both as consequence of a high fat diet (Balsevich et al., 2014), and after a 
24h food deprivation period (Guarnieri et al., 2012). Furthermore, Fkbp5 depletion was 
revealed to protect against high fat diet-induced weight gain and hepatic steatosis (Cho et 
al., 2001; Stechschulte et al., 2016). A more recent study showed that loss of Fkbp51 in mice 
markedly improves metabolism, in particular glucose tolerance in both control and high fat 
diet conditions (Balsevich et al., 2017).  
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At the cellular level, FKBP51 has been found to regulate a plethora of intracellular 
pathways that have been characterized by cellular and biochemical studies. In an HSP90 
interactome study, Taipale and colleagues identified an unexpectedly vast and diverse 
repertoire of FKBP51 interactors. FKBP51 was found to bind to kinases, Argonaut proteins, 
transcription factors, and subunits of the minichromosome maintenance (MCM) protein 
complex (Taipale et al., 2014). Furthermore, several studies evidenced the role of FKBP51 
in the regulation of numerous pathways involved in physiology and disease (Table 1). This 
growing body of evidence presents FKBP51 as a central hub of various cellular pathways, 
independently of its role in GR inhibition. These studies, together with the knowledge that 
FKBP51´s expression is enhanced by stress, make this protein a stress mediator, or “switch”, 
for a plethora of cellular functions. 
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Table 1 – Literature review of FKBP51-regulated cellular pathways. List of pathways that are regulated by FKBP51, the effects exerted by FKBP51 on each 
pathway, the main interactors of FKBP51 for each pathway, possible implications in disease and study reference.
Pathway Exerted effect FKBP51 interactor Related disease Study 
GC signalling Inhibited GR activity via HSP90 interaction HSP90 Stress-related disorders (Sanchez, 2012)  
Androgen signalling Enhanced transcriptional activation of AR  HSP90 Prostate cancer, resistance to anti-cancer therapies 
(Ni et al., 2010; 
Periyasamy et al., 
2010) 
Progesterone 
signalling Inhibited PR (progesterone receptor) activity HSP90  (Barent et al., 1998) 
NFAT Enhanced NFAT-regulated gene expression CaN inflammation (Li et al., 2002) 
NF-kB Enhanced NF-kB-mediated transcription via inhibition of the NF-kB inhibitor IkB IKK, TRAF2 
Inflammation, cardiovascular 
diseases , cancer, resistance 
to anti-cancer therapies 
(Bouwmeester et al., 
2004; Romano et al., 
2015a) 
JAK/STAT Induced apoptotic resistance to cytokine deprivation via STAT hyperactivation Hypothesized JAK2 cancer (Komura et al., 2003) 
Rho-ROCK signaling Enhanced cell motility and invasion of cancer cells via upregulation of RhoA activity and enhanced Rho-ROCK signaling. DLC1, DLC2 cancer (Takaoka et al., 2017) 
CDK4 Stabilized CDK4 levels and kinase function CDK4 cancer (Jirawatnotai et al., 2014) 
mTOR Inhibited mTOR catalytic activity triggered by rapamycin mTOR (in complex with rapamycin) Cancer, autophagy (Hausch et al., 2013) 
Macroautophagy Enhanced macroautophagy activation AKT1, PHLPP, Beclin1  (Gassen et al., 2014) 
GSK3B signalling Increased effect of antidepressants and lithium via GSK3B inhibition CDK5, GSK3B  (Gassen et al., 2016) 
DNA methylation Decreased DNA methylation via inhibition of DNMT1 DNMT1, CDK5  (Gassen et al., 2015a)  
Microtubules 
polymerization Enhanced microtubule polymerization via tau dephosphorylation Tau, PP5 Alzheimers disease (Jinwal et al., 2010) 
AKT2-AS160 
signaling Dephosphorylated and consequently inactivated AKT2 and AS160  AKT2, AS160, PHLPP Type 2 dyabetes 
(Balsevich et al., 
2017) 
miRNA maturation Enhanced AGO2 transcription and facilitade RISC assembly AGO2  (Martinez et al., 2013) 
store-operated 
calcium entry 
current (ISOC) 
Inhibited ISOC via PP5-mediated dephosphorylation PP5  (Hamilton et al., 2018) 
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1.2.5. Regulation of autophagy  
A particularly interesting function in which FKBP51 exerts its “switch” role is 
macroautophagy, a cellular mechanism able to maintain homeostasis and manage stress 
responses. Autophagy, of which macroautophagy is a subtype, is an important quality control 
process in physiological and pathological states (Mizushima and Komatsu, 2011; Mizushima et 
al., 2008). It maintains energy and nutrient supplies during starvation or absence of growth 
factors (Galluzzi et al, 2014), prevents accumulation of protein aggregates, controls organelle 
quality and quantity in the cell, and has antimicrobial and other immune functions (Randow & 
Youle, 2014; Rubinsztein et al, 2015; Sica et   al, 2015; Khaminets et al, 2016). The regulation of 
macroautophagy by FKBP51 can be considered an additional regulatory process of the stress-
response at the cellular level. In the presence of a stressor (GR activation), FKBP5 expression is 
increased and enhances macroautophagy activation via interaction with the kinase AKT and the 
macroautophagy initiatoir Beclin 1 (Gassen et al., 2015b), restoring cellular and protein 
homeostasis after stress. Besides macroautophagy, there are other autophagy pathways 
governed by autophagy-related (ATG) proteins, and they can be distinguished into two main 
types: 1) lytic autophagy: proteins, microbes and damaged organelles recycled and degraded 
to respectively maintain cellular homeostasis in accordance to energy availability and ensure 
cellular health and functionality; 2) secretory autophagy: the cytoplasmic cargo is secreted into 
the extracellular matrix either for signaling purposes or as a disposal mechanism. Recent 
studies suggest that secretory autophagy plays an important role in extracellular signaling of 
immune response (Cadwell et al., 2008; Ushio et al., 2011; Michaud et al., 2011; Deretic et al, 
2013). Nevertheless, the exact mechanisms controlling secretory autophagy are still under 
investigation. Depending whether the selection of the material to be degraded is targeted or 
unspecific, lytic autophagy can be further subdivided into selective and non-selective. To the 
second one belong micro- and macro-autophagy. In microautophagy, the lysosomal membrane 
is invaginated and differentiated into the autophagic tube enclosing random portions of the 
cytosol for degradation (Li et al., 2012).  Conversely, in macroautophagy, the first and most 
studied type of autophagy, non-selective substrates are first sequestered into double-
membrane vesicles termed autopahgosomes. These are then fused with lysosomes, forming 
autolysosomes, where the content is degraded (Klionsky, 2005). However, macroautophagy 
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can also be highly specific in terms of type of engulfed organelle, resulting in selective 
organellophagy (mitophagy, ribophagy, etc.). This specificity is promoted by the initiating 
stimulus that causes a specific homeostatic perturbation, increasing the availability of distinct 
autophagic substrates, in opposition to a general stress stimulus that demands non-specific 
autophagic regulation (Okamoto, 2014). A more selective kind of autophagy is the chaperone-
mediated autophagy (CMA). Here, only single proteins, recognized by a KFERQ or KFERQ-like 
motif in the amino acid sequence are targeted and transported to the lysosomal lumen by the 
heat shock-cognate chaperone 70 (HSC70) (Alfaro et al., 2019). Although each autophagic 
pathway has specific regulators, ATG proteins are a common denominator of all types of 
autophagy and their involvement defines autophagy as such. All these autophagic processes 
are activated in response to different stimuli and stressors, and represent a fundamental 
mechanism that not only maintains a correct proteostasis but also preserves the homeostasis 
of the whole organism. So far, only cellular stressors such as starvation and oxidative stress 
have been analyzed as trigger for most of these autophagic pathways. The evidence collected 
from the study by Gassen et al. shed some light on the link between environmental stress and 
autophagy, unveiling this as a possible mechanism regulating the stress response at the cellular 
level. The effect of GCs on other autophagic pathways, however, remains unknown. 
 
1.2.6. Splicing variants and protein isoforms: the unexplored FKBP5 
Despite being among the most investigated genes in psychiatric research, there remains a 
major lack of knowledge regarding the splicing variants and protein isoforms of FKBP5/51. To 
date, four transcription variants (variant 1-4) of the human FKBP5 have been annotated, coding 
for two different isoforms (isoform 1 and 2) of the protein FKBP51. Thus far, only a few studies 
carried out by the lab of M.F. Romano at the University of Naples, Italy, have investigated 
isoform 2 in association to the development of melanoma and glioma (D’Arrigo et al., 2017; 
Romano et al., 2015b). A reason for the lack of distinction between the isoforms in the literature 
might be the fact that in mice, from which a large body of current knowledge on FKBP5/51 
comes, only one isoform of FKBP51 is annotated. In humans, transcription variant 1 
(ENST00000357266.8) differs in the 5’ UTR from variants 2 (ENST00000536438.5) and 3 
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(ENST00000539068.5) and all three code for the 475 amino acid (aa) long isoform 1 (Q13451-
1), while variant 4 (ENST00000542713.1) corresponds to a much shorter transcript and codes 
for the “truncated” isoform 2 (Q13451-2) of 268 aa (fig. II). Gene expression data 
(www.genesapiens.org) indicate that FKBP5 is ubiquitously expressed with particularly high 
expression levels in bone marrow myeloid cells, muscle and adipose tissue. The little 
information available on the expression of the different transcription variants indicates that 
variant 4 is less expressed than variant 1, but slightly more than variants 2 and 3 in most of the 
human tissues. In the brain, the expression of variant 1 and 4 is the lowest among all the tissues, 
while variants 2 and 3 are undetectable (www.gtexportal.org). Therefore, we can assume that 
in all experiments conducted without distinguishing between the different variants, the overall 
expression levels mirror mainly the ones of variant 1. 
At the protein level, FKBP51 isoform 1 has two N-terminal FK506-binding (FK) domains and 
three tetratricopeptide repeat (TPR) motifs at the C-terminus. Isoform 2 of FKBP51 coincides 
with isoform 1 for the first 222 aa, corresponding to the FK domains. The sequence ranging 
from aa 223 to its C-terminus (aa 268) is unique and, so far, uncharacterized. Missing the rest 
of isoform 1’s C-terminal region, isoform 2, therefore, lacks the TPR motifs (fig. II b). The first 
FK domain, FK 1, is the binding site of the immunosuppressive drug FK506, from which the 
protein gets its name. FK1 also exerts a peptidyl-prolyl cis-trans isomerase (PPIase) or rotamase 
activity (Schiene and Fischer, 2000), characteristic of all immunophilins. The pocket in FK1 is 
also the binding site for another drug, rapamycin. This drug, in complex with FKBP51, exerts 
immunosuppressive and anticancer effects, mediated via the selective inhibition of the 
mechanistic target of rapamycin (mTOR) (Sabatini, 2006). Downstream, adjacent to FK1, is the 
second FK domain, FK2, that is presumably derived from a duplication event of the FK1 domain 
and shares 32% sequence homology with it (Cioffi et al., 2011), but lacks measurable rotamase 
activity (Sinars et al., 2003) and does not bind FK506. Instead, it might have cooperative 
functions with the TPR motifs (Sinars et al., 2003). The TPR motifs at the C-terminus promote 
protein-protein interactions (Russell et al., 1999), in particular with chaperone proteins such as 
HSP90 and heat shock protein 70 (HSP70) (Dornan and Walkinshaw, 2003). Furthermore, Li et 
al. showed that the TPR motifs are also responsible for the interaction with the serine-
threonine phosphatase calcineurin (CaN). This phosphatase activates nuclear transcription 
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factors of activated T lymphocytes (NFAT), responsible for the expression of interleukin-2 (IL2) 
and several T cell specific activators, regulating thereby the clonal expansion of T cells after 
stimulation by an antigen (Li et al., 2002). These domain-dependent roles suggest differential 
functions for the two isoforms, whose investigation would be of particular interest due to the 
scarce literature regarding their distinctive roles. 
 
 
 
 
Figure II – FKBP51 splicing variants and isoforms. a) Schematic view of the FKBP5 locus on human 
chromosome 6 and the four splicing variants of the gene. b) Schematic view of FKBP51 isoform 1 and 
2 protein structures. c) 3D structure models generated with the swiss model repositoty server of the 
expasy portal (https://swissmodel.expasy.org/). Domains are indicated in black and experimentally 
validated domain-associated binding partners in blue. 
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2. Rationale and aims 
The overarching aim of this work is to deepen the understanding of how FKBP51 modulates 
the effect of stress to trigger a cellular response able to promote and restore homeostasis.  
In the first part of my work, I will investigate the regulatory role of FKBP51 in autophagy, as 
this is a cellular mechanism able to maintain homeostasis and manage stress responses. In 
particular I will focus on a selective type of autophagy, the chaperone-mediated autophagy, to 
understand the effect of stress on selective protein homeostasis (proteostasis), and on 
secretory autophagy, a non-lytic, autophagic mechanism that has been linked to immune 
response, but whose role is still unclear. 
The second part of this work is dedicated to a better characterization of FKBP51. Despite 
being vastly investigated both at the genetic and protein level, there is a lack of knowledge 
regarding its splicing variants and isoforms. Given its vast involvement in the regulation of a 
plethora of cellular functions, a better understanding of possible differential roles of FKBP51 
isoforms and their dynamics, might contribute not only to a deeper understanding of FKBP51’s 
functions, but also enhance the possibility for a more precise targeted drug design.   
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3. Materials and Methods 
3.1. Study design 
To answer my research questions, different approaches were used. Most of the investigation 
was conducted in vitro, using different cell lines, accordingly to the aim of the experiment. 
To assess the role of stress in chaperone-mediated autophagy (CMA), we used pulse chase 
assays that allowed us to quantify the net degradation of selected proteins excluding the new 
synthesis. The involvement of FKBP51 was determined with the use of CRISPR-Cas9-generated 
FKBP51 KO cells. Successively, the molecular interactions of the CMA-regulating complex was 
elucidated via lysosome extraction followed by immunoprecipitation (IP) of key proteins. A 
proteome wide effect of stress-triggered CMA was then assessed via pulse-SILAC mass 
spectrometry through which the extent of stress-triggered CMA could be analyzed and novel 
targets could be detected. 
To investigate the possible role of FKBP51 in other and novel cellular pathways we analyzed 
its interactor partners. Spectrometry analysis, was used to find the novel interactor of FKBP51 
Sec22b that led to the investigation of the role of FKBP51 in the secretory autophagy pathway. 
The regulatory complex of the pathway was further tested via IP. To examine the functional 
effect of stress and FKBP51 on secretory autophagy, different secreted target proteins were 
analyzed via ELISA and hippocampal microdyalisis in vitro and in vivo respectively. Lastly, the 
global effect of GC on secretory autophagy was observed and novel secreted proteins were 
detected via quantitative secretome analysis.  
Given the plethora of functions of FKBP51, the need to a better characterization of the 
different isoforms led to a basal characterization in HeLa cells of Dex responsiveness of the 
different transcription variants via qPCR. Furthermore degradation dynamics of the two 
isoforms of FKBP51 was analyzed via pulse chase assay. FKBP51 KO cell model was generated 
via CRISPR-Cas9 to better analyze the role of the different isoforms. Differential intracellular 
localization of the two GFP-tagged FKBP51 isoforms was observed with epifluorescence 
microscopy. The differential role of the two isoforms in different pathways known to be 
regulated by FKBP51 was examined via WB analyses of downstream targets regulated by 
overexpression of the different isoforms. 
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3.2. Methods 
3.2.1. Cell culture  
The human cell lines HeLa and SY-SY5Y were cultured at 37°C, 6% CO2 in Dulbecco's 
Modified Eagle Medium (DMEM) high glucose with GlutaMAX (Thermo Fisher, 31331-028), 
supplemented with 10% fetal bovine serum (Thermo Fisher, 10270-106) and 1% antibiotic-
antimycotic (Thermo Fisher, 15240-062).  
The murine microglia cell line SIM-A9 was cultured at 37°C, 6% CO2 in Dulbecco's Modified 
Eagle Medium (DMEM) high glucose with GlutaMAX (Thermo Fisher, 10566016), supplemented 
with 10% fetal bovine serum (Thermo Fisher, 10270-106), 5% horse serum (Thermo Fisher, 
16050-122) and 1%  antibiotic-antimycotic (Thermo Fisher, 15240-062).  
3.2.2. Transfections  
Jurkat cells (2 × 106; suspension cells), or with 1x trypsin-EDTA (gibco, 15400-054) detached 
HeLa, SH-SY5Y or SIM-A9 cells (2 × 106) were resuspended in 100 µl of transfection buffer [50 
mM Hepes (pH 7.3), 90 mM NaCl, 5 mM KCl, and 0.15 mM CaCl2]. Up to 2 µg of plasmid DNA 
was added to the cell suspension, and electroporation was carried out using the Amaxa 2B-
Nucleofector system (Lonza). Cells were replated at a density of 105 cells/cm2. 
For the intracellular localization experiments, Hela cells were transfected with 
Lipofectamine 3000 transfection reagent (Thermo Fisher, L3000001) according to the supplier’s 
protocol. 
3.2.3. Western Blot Analysis 
Protein extracts were obtained by lysing cells in 62.5 mM Tris, 2% SDS, and 10% sucrose, 
upplemented with protease (Sigma, P2714) and phosphatase (Roche, 04906837001) inhibitor 
cocktails. Samples were sonicated and heated at 95 °C for 5 min. Proteins were separated by 
SDS-PAGE and electro-transferred onto nitrocellulose membranes. Blots were placed in Tris-
buffered saline solution supplemented with 0.05% Tween (Sigma, P2287) (TBS-T) and 5% non-
fat milk for 1 hour at room temperature and then incubated with primary antibody (diluted in 
TBS-T) overnight at 4 °C. Subsequently, blots were washed and probed with the respective 
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horseradish-peroxidase- or fluorophore-conjugated secondary antibody for 1 hour at room 
temperature. The immuno-reactive bands were visualized either using ECL detection reagent 
(Millipore, WBKL0500) or directly by excitation of the respective fluorophore. Recording of the 
band intensities was performed with the ChemiDoc MP system from Bio-Rad. 
3.2.3.1. Quantification of Protein Data 
All protein data were normalized to Actin or GAPDH, which was detected 
on the same blot. In the case of AKT phosphorylation, the ratio of pAKTS473 to total AKT was 
calculated. Similarly, the direct ration of LC3BII over LC3BI is also provided, as well as the ratio 
over Actin. 
3.2.4. Real time quantitative polymerase chain reaction (RT-qPCR) 
Total RNA was isolated from HeLa cells with the RNeasy mini kit (Qiagen, 74104) following 
the manufacturer’s protocols. Reverse transcription was performed using SuperScript II reverse 
transcriptase (Thermo Fisher, 18064014). Subsequently, the cDNA was amplified in triplicates 
with the LightCycler 480 Instrument II (Roche, Mannheim, Germany) using primers from IDT 
and TaqMan™ Fast Advanced Master Mix (Thermo Fisher, 4444964).   
3.2.5. CRISPR-Cas9 KO generation 
 Generation of SIM-A9 Atg5 KO cell line: using Lipofectamine 3000 transfection reagent 
(Thermo Fisher Scientific, L3000001), cells were transfected with CRISPR-Cas9 Atg5 plasmid. 48 
hours after transfection 2 µg/ml of puromycin (InvivoGen, ant-pr-1) was added to the medium. 
After 36 hours the medium was changed and single clones were manually picked and replated 
in single wells for expansion. KO clones were selected via western blot analyses.  
Generation of FKBP5 KO HeLa cell line: using Lipofectamine 3000 transfection reagent 
(Thermo Fisher, L3000001), cells were transfected with a pool of three CRISPR/Cas9 plasmids 
containing gRNA targeting human FKBP5 and a GFP reporter (Santa Cruz, sc-401560). 48 hours 
post transfection, cells were FACS sorted for GFP as single cells into a 96-well plate using BD 
FACS ARIA III ) in FACS medium [PBS, 0.5% BSA Fraction V, 2 mM EDTA, 20mM Glucose, and 100 
U/mL Penicillin-Streptomycin]. Single clones were expanded and western blotting was used to 
validate the knockouts. 
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For the generation of FKBP5 KO SH-SY5Y cell line, cells were co-transfected with a pool of 
three CRISPR/Cas9 plasmids containing gRNA targeting human FKBP5 and a GFP reporter (Santa 
Cruz, sc-401560) together with a homology directed repair plasmid (sc-401560-HDR) consisting 
of 3 plasmids, each containing a homology-directed DNA repair (HDR) template corresponding 
to the cut sites generated by the FKBP51 CRISPR/Cas9 KO Plasmid (sc-401560). 48 hours after 
transfection, medium was changed to 2 µg/ml puromycin-containing medium. After 36 hours 
single clones were manually picked and replated in single wells for expansion. KO clones were 
selected via western blot analyses. 
3.2.6. Lysosome extraction 
Cells were cultured in serum deprived medium for 72 hours prior to the experiment in order 
to enhance CMA. Dex or vehicle were added to the media 24 hours prior to the experiment. 2 
x 108 SH-SY5Y cells were used for each condition. Lysosomes were extracted following 
manufacturer instructions with the lysosomal isolation kit (Sigma, LYSISO1). Briefly, cells were 
washed with PBS and homogenized in the extraction buffer provided with the kit. 200 µl were 
kept as whole cell lysate. After centrifugation, the crude lysosomal fraction was separated by 
density gradient centrifugation (150,000×g for 4 hours) on a multi-step OptiPrep gradient. All 
fractions were tested for LAMP2A  by western blotting and for each condition, the fraction 
containing LAMP2A was used for further analysis as the lysosomal fraction. 
3.2.7. Co-immunoprecipitation 
In case of FLAG- or GFP-tag immunoprecipitation, cells were cultured for 3 days after 
transfection. Cells were lysed in CoIP buffer [20 mM tris-HCl (pH 8.0), 100 mM NaCl, 1 mM 
EDTA, and 0.5% Igepal complemented with protease inhibitor cocktail (Sigma)] for 20 min at 4 
°C with constant mixing. The lysates were cleared by centrifugation, and the protein 
concentration was determined and adjusted (1.2 mg/ml); 1 ml of lysate was incubated with 2.5 
µg of FLAG or GFP antibody overnight at 4 °C with constant rotating. Subsequently, 20 µl of 
bovine serum albumin–blocked protein G Dynabeads (Invitrogen, 100-03D) were added to the 
lysate-antibody mix followed by a 3 hour incubation at 4 °C. Beads were washed three times 
with PBS, and bound proteins were eluted with 100 µl of 1 × FLAG peptide solution (100 to 200 
ug × ml−1, Sigma F3290) in PBS for 30 min at 4 °C. In case of precipitation of GFP tag, elution 
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was performed by adding 60 µl of Laemmli sample buffer and by incubation at 95 °C for 5 min. 
5 to 15 µg of the input lysates or 2.5 to 5 µl of the immunoprecipitates were separated by SDS–
polyacrylamide gel electrophoresis (PAGE) and analyzed by western blotting. When quantifying 
co-immunoprecipitated proteins, their signals were normalized to input protein and to the 
precipitated interactor protein. 
3.2.8. Subcellular fractionation 
Subcellular fractionation was performed according to Suzuki et al., 2010 with little 
modifications. Briefly, 48 hours after transfection, 1x106 cells were harvested on ice with a 
plastic scraper and centrifuged for 30 sec with a mini centrifuge. After the supernatant was 
discarded, pellets were resuspended in 200 µl REAP buffer [0.1% NP40/PBS] and triturated 5x 
with a p1000 micropipette. 50 μl of the lysate were removed as "whole cell lysate" and 16 μl of 
4 × Laemmli sample buffer were added to it. The remaining (150 μl) material was centrifuged 
for 30 sec and 75 μl of the supernatant was removed as the "cytosolic fraction". 25 μl of 4 × 
Laemmli sample buffer was added to this fraction. After the remaining supernatant was 
removed, the pellet was resuspended in 100 μl of ice-cold REAP buffer and centrifuged as above 
for 30 sec and the supernatant was discarded. The pellet was resuspended in 75 μl of 1 × 
Laemmli sample buffer and designated as "nuclear fraction". All samples were boiled at 95 °C 
for 5 min and stored at -20 °C.   
3.2.9. Reporter gene assays 
Reporter gene experiments were performed in 96-well plates. 2 × 106 cells were transfected 
with 1 ug TCF/LEF-Luc, 100 ng pCMV-Gaussia-Luc, and, in case of simultaneous overexpression 
experiment, 1ug pRK5-FKBP51v1/v4-plasmid. Dex treatment was for 4 hours. To determine 
Firefly luciferase activity, cells were lysed in 50 μl passive lysis buffer [0.1 M K2HPO4/KH2PO4 
pH 7.8, 0.2% Triton X-100]; 50 μl of luciferase reaction buffer [33 mM K2HPO4/KH2PO4, pH 7.8, 
1.7 mM ATP, 3.3 mM MgCl2 and 13 mM luciferin] to a fraction of 10 μl of cell lysate were added 
and luminometric readings were performed with an automatic counter (Tristar from Berthold, 
Wildbad, Germany). Activity of the secretory Gaussia luciferase38 was measured after addition 
of 50 μl of substrate/buffer [1.1 M NaCl, 2.2 mM EDTA, 0.22 M KPO4 pH 5.1, 0.44 mg ml-1 
bovine serum albumin, and 0.5 mg ml − 1 coelenterazine].  
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3.2.10. Immunocytochemistry 
Cells were cultured on cover glasses (Paul Marienfeld, 0117530). When ready to be 
processed, cells were fixed with 4% PFA/PBS for 10 min at room temperature, permeabilized 
with 0.3% Triton X-100/ PBS for 5 min at room temperature and blocked with blocking solution 
[3% bovine serum albumin, 10% donkey serum in 0,1% Tween20 PBS] for 1 hour at room 
temperature. Cells were then incubated with primary antibodies diluted in blocking solution 
overnight at 4 °C and with the appropriate fluorophore-coupled secondary antibodies diluted 
in blocking solution for 1 hour at room temperature. Cells were counterstained with DAPI 
(Sigma D9542) diluted in PBS-T for 5 min and then mounted on imaging slides with Aqua-
Polymount (Polyscience, 18606).  
3.2.11. Pulse chase assay 
48 hours after transfection with halotag (HT)-tagged plasmids, cells were labeled with HT 
fluorescent ligands (HaloTag R110Direct Ligand, Promega) for 24 hours after which the 
fluorescent ligand was washed off (chase) for the indicated amounts of time. Cells were 
harvested, proteins extracted minimizing light exposure and western blots were performed. 
Fluorescence was successively measured on membrane with the ChemiDoc MP system from 
Bio-Rad. 
3.2.12. ELISA 
The Il1b solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) (Thermo Fisher, 
# BMS6002) was performed according to the manufacturer protocol. Briefly, microwells were 
coated with mouse anti-Il1b antibody followed by a first incubation with biotin-coupled anti 
mouse antibody, a second incubation with streptavidin-HRP and a final incubation with the SIM-
A9 culture medium. Amounts of Il1b were detected with a plate reader (iMARK, Bio-Rad) at 450 
nm. 
3.2.13. In vivo brain microdialysis in mice 
Microdialyses were performed by the in-house analytics and mass spectrometry core facility 
as in Anderzhanova et al., 2013, Kao et al, 2015 and Yen et al., 2015.  
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Briefly, stereotaxic implantation of microdialysis probe guide cannula was performed 7 days 
before the probe implantation and, respectively, 8 days before the start of an experiment. One 
day before the actual experiment, microdialysis probes were inserted and connected to the 
perfusion lines. All perfusion line connections were secured via wired-mediated attachment of 
the metal peg and swivel. The shape of the perfusion lines was tailored to minimize both inlet 
and outlet total volumes (this reduces the back pressure and lag time). From the moment of 
insertion, the probe was continuously perfused with sterile Ringer’s solution (Biooscientific, 
USA) at a flow rate of 0.3 μl/min with high precision perfusion pump (Harvard Apparatus, USA). 
On the experimental day, microdialysis fractions (30 min) were constantly collected into Protein 
LoBind tubes (Eppendorf, Germany) at a perfusion rate of 0.4 μl/min. During collection time, 
tubes were kept on ice at 4 °C.  After collection of two baseline samples animals were 
transferred to the fear conditioning chamber (ENV-407, ENV-307A; MED Associates, 7 St 
Albans, VT, USA connected to constant electric flow generator (ENV-414; MED Associates) and 
a foot shock (1.5 mA x 1 sec x 2) was delivered. After this procedure mice were returned to the 
microdialysis cage were two post-footshock samples were collected. To examine an effect of 
ULK1 inhibitor MRT 68921 on stress-evoked changes in extracellular content of proteins the 
drug was injected intraperitoneally (i.p.) in a dose of 5.0 mg/kg and in a volume 10 ml/kg  four 
hours before the moment of foot shock (the drug was prepared freshly dissolving a stock 
solution [60%EthOH/40% DMSO mixture] with saline in proportion 1:20). Once collected, 
samples were stored at −80 °C prior to analysis. After completing the microdialysis procedure, 
mice were anaesthetized with isoflurane (3-4 % v/v in air), the microdialysis probe were 
removed, the animals were sacrificed via cervical dislocation (under anaesthesia) and brains 
were collected. 40 µm brain sections were stained with cresyl violet (Carl Roth GmbH, 
Germany) and probe placement was verified under a microscope using Paxinos and Franklin 
(2001) mouse atlas. If probe placement was found to be out of the targeted region of interest, 
the respective samples were excluded from the study.  
3.2.14. CMA proteomics analyses 
Liquid chromatography and mass spectrometry (LC-MS/MS) analysis and peptide and 
protein identification and quantification were performed by the proteomics and mass 
spectrometry core facility of the Max Planck Institute of Biochemistry (Martinsried, Germany).  
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3.2.14.1.  (LC-MS/MS)  
Peptides were separated by liquid chromatography performed on an EASY-nano-LC 
(Thermo Fisher Scientific) coupled with a nanoelectrospray-source to a Q Exactive™ HF Hybrid 
Quadrupol-Orbitrap mass spectrometer (Thermo Fisher Scientific). LyseC digested Peptides 
were solved in buffer A [H2O with 0.1% formic acid] and  separated with an isocratic gradient 
30% buffer B [80% acetonitrile with 0.1% formic acid] for 120 min followed by a column wash 
step and re-equilibration at a flow rate of 250 nl/min. Precursor ions were measured at a 
resolution of 60’000 (scan range: 300-1750 m/z) and a target value of 3e6 ions. The 15 most 
intense ions from each MS scan were isolated, fragmented, and measured with a resolution 
of 15’000 (scan range: 200-2000 m/z) and a target value of 1e5. 
3.2.14.2. Peptide and Protein identification and quantification 
The MaxQuant software (version 1.5.3.34) was used for the analysis of raw files, and peak 
lists were searched against the human UniProt FASTA reference proteomes and a common 
contaminants database by the Andromeda search engine. Cysteine carbamidomethylation 
was used as a fixed modification, and methionine oxidation and protein N-terminal 
acetylation as variable modifications. Lysin/C was specified as the proteolytic enzyme and up 
to four missed cleavage sites were allowed. The FDR was set to 1%. 
3.2.14.3. Data analysis 
Only the light isotope signal was used for analysis. The Perseus software suite (v. 1.6.0.9) 
was used to filter out contaminants, reverse hits and protein groups, which were only identified 
by site. Only protein groups that were detected in at least two out of the three replicates in at 
least one condition were considered for the analysis.  
The filtered data was log normalized and missing values were imputed according to the 
normal distributed imputation algorithm implemented in the Perseus framework. Default 
values were used (width: 0.3; down shift: 1.8). To find the significantly regulated protein groups 
a volcano plot analysis was performed using the default settings (s0= 0.1; FDR= 0.05). The 
results were exported for further enrichment analyses performed on the reactome platform 
(www.reactome.org). 
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3.2.15. Interactome analyses 
Interactome analyses were performed in-house by the C. Turck lab as part of a collaboration. 
3.2.15.1. Sample preparation  
HEK cells were transfected with a FLAG tagged FKBP51 expressing plasmid or a FLAG 
expressing control vector. 48 hours after transfection, a FLAG IP was performed on all the 
samples and the eluted proteins were separated by SDS gel electrophoresis. Separated proteins 
were stained with Coomassie staining solution for 20 min and destained over night with 
Coomassie destaining solution. Each gel lane was cut into 16 approximately 2.5 mm slices per 
biological replicate and these further cut into smaller gel pieces.  
3.2.15.2. In-gel-trypsin digestion and peptide extraction  
The gel pieces were covered with 100μl of 25 mM Na4HCO3/50% ACN in order to destain 
the gel pieces completely and mixed for 10 min at room temperature. The supernatant was 
discarded and this step was repeated twice. Proteins inside the gel pieces are reduced with 75 
µl 1x DTT/25 mM NH4HCO3 mixed at 56 °C for 30 min in the dark. The supernatant was 
discarded and 100μl IAM were added for alkylation to the gel pieces and mixed for 30 min at 
room temperature. The supernatant was discarded and the gel pieces washed twice with 100μl 
25 mM Na4HCO3/50% ACN and mixed for 10 min at room temperature. The supernatant was 
discarded and gel pieces were dried for approximately 20 min at room temperature. Proteins 
were digested with 50 μl trypsin solution [5 ng/μl trypsin/25 mM NH4HCO3] over night at 37 °C. 
Peptides were extracted from the gel pieces by mixing them in 50 μl of 2% FA/50% ACN for 20 
min at 37 °C and subsequently sonicating them for 5 min. The supernatant contained the 
peptides. This step was repeated twice with 50 μL of 1% FA/50% ACN.  
3.2.15.3. LC MS/MS 
Tryptic peptides were then dissolved in 0.1% FA and analyzed with a nanoflow HPLC-2D 
system (Eksigent, Dublin, CA, USA) coupled online to an LTQ-Orbitrap XLTM mass spectrometer. 
Samples were on-line desalted for 10 min with 0.1% FA at 3 μl/min (Zorbax-C18 (5 μm) guard 
column, 300 μm × 5 mm; Agilent Technologies, Santa Clara, CA, USA) and separated via RP-C18 
(3 μm) chromatography (in-house packed Pico-frit column, 75 μm × 15  cm, New Objective, 
Woburn, MA, USA). Peptides were eluted with a gradient of 95% ACN/0.1% HCOOH from 10% 
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to 45% over 93 min at a flow rate of 200 nl/min. Column effluents were directly infused into 
the mass spectrometer via a nanoelectrospray ion source (Thermo Fisher Scientific). The mass 
spectrometer was operated in positive mode applying a data-dependent scan switch between 
MS and MS/MS acquisition. Full scans were recorded in the Orbitrap mass analyzer (profile 
mode, m/z 380–1600, resolution R = 60000 at m/z 400). The MS/MS analyses of the five most 
intense peptide ions for each scan were recorded in the LTQ mass analyzer in centroid mode. 
The peptides were then identified with Mascot Daemon (Matrix Sciences London, 
http://www.matrixscience.com/daemon.html). Proteins were considered with a score ≥ 50 and 
≥ 2 peptide matches and searched within the Swiss-Prot database FDR ≤ 0.05. 
3.2.16. Secretome analyses 
LC-MS/MS analysis and peptide and Protein identification and quantification were 
performed by the Bernhard Küster lab of the Technical University Munich (TUM) as part of a 
collaboration. 
3.2.16.1. Sample preparation 
All samples were prepared in triplicates. For each replicate 2 x 150 mm culture dishes, 
containing each 20 ml of medium, were used. WT and Atg5 KO SIM-A9 cells were cultured in 
methionine-free medium [DMEM, high glucose, no glutamine, no methionine, no cystine 
(Thermo Fisher, 21013024), 2 mM L-Glutamine (Thermo Fisher, 25030081), 1 mM sodium 
pyruvate (Thermo Fisher, 11360070), 0.2 mM L-Cysteine (Sigma, C7352), 10% dialyzed FBS 
(Thermo Fisher, 30067334), 1%  Antibiotic-Antimycotic (Thermo Fisher, 15240-062)] for 30 min 
(12 hours and 30 min before supernatant collection). After 30 min, medium was changed to 
AHA enriched medium [methionine-free medium with 20 µM Click-IT™ AHA (L-
Azidohomoalanine) (Thermo Fisher, C10102)] to lable newly synthetysed proteins. After 6 
hours, cells were treated with 100 nM Dex or vehicle at a dilution of 1:10’000 (6 hours before 
supernatant collection). After 3 hours (3 hours before supernatant collection), all media were 
refreshed in order to analyze proteins that were secreted only during the last 3 hour time 
window. After 3 hours, supernatants were collected and centrifuged at 1000 x g for 5 min. 
EDTA-free proteinase inhibitor cocktail (Sigma, S8830) was added and supernatants were 
frozen at -20°C. The next day, supernatants were thawed on ice and concentrated with Amicon 
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Ultra 15 centrifugal filters, Ultracell 3K (Millipore, UFC900324) at 4000 x g at 4 °C for 5 hours. 
The concentrated samples were transferred into new 1.5 ml tubes (Sigma, Z606340). For the 
enrichment and digestion of AHA-labeled proteins, the Click-iT™ Protein Enrichment Kit 
(Thermo Fisher Scientific) was used according to the instructions of the supplier. Resulting 
peptides were further desalted by using 0.1 % formic acid in 50 % acetonitrile in the micro-
column format (three discs, Ø 1.5 mm, C18 material, 3M Empore per micro-column were used). 
After drying in a centrifugal evaporator, the samples were stored at -20 °C until LC-MS/MS 
analysis. 
3.2.16.2. LC-MS/MS 
LC-MS/MS measurement of peptides in eluates was performed using a nanoLC UltiMate 
3000 (Thermo Fisher Scientific) coupled to a quadrupole-Orbitrap Q Exactive HF-X mass 
spectrometer (Thermo Fisher Scientific). Peptides separated on an Acclaim PepMap analytical 
column (0.1 mm x 15 cm, C18, 2 µM, 100 Å; Thermo Fisher Scientific) using a 60 min linear 
gradient from 3-28 % solvent B [0.1 % formic acid, 5 % DMSO in acetonitrile] in solvent A [0. 1% 
formic acid, 5 % DMSO in water] at a flow rate of 10 µL/min. The mass spectrometer was 
operated in data dependent acquisition and positive ionization mode. MS1 spectra were 
acquired over a range of 360-1300 m/z at a resolution of 60’000 in the Orbitrap by applying an 
automatic gain control (AGC) of 3e6 or maximum injection time of 50 ms. Up to 12 peptide 
precursors were selected for fragmentation by higher energy collision-induced dissociation 
(HCD; 1.3 m/z isolation window, AGC value of 1e5, maximum injection time of 22 ms) using 28 
% normalized collision energy (NCE) and analyzed at a resolution of 15’000 in the Orbitrap.  
 
3.2.16.3. Peptide and Protein identification and quantification 
Peptide and protein identification and quantification was performed  using MaxQuant  
(version 1.6.0.16) by searching the tandem MS data against all murine canonical and isoform 
protein sequences as annotated in the Swissprot reference database (25175 entries, 
downloaded 13.07.2018) using the embedded search engine Andromeda. 
Carbamidomethylated cysteine was set as fixed modification and oxidation of methionine and 
N-terminal protein acetylation as variable modification. Trypsin/P was specified as the 
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proteolytic enzyme and up to two missed cleavage sites were allowed. Precursor tolerance was 
set to 4.5 ppm and fragment ion tolerance to 20 ppm. The minimum peptide length was set to 
seven and all data were adjusted to 1 % PSM and 1 % protein FDR. Intensity-based absolute 
quantification (iBAQ) was enabled within MaxQuant.  
 
3.2.16.4. Data analysis 
The Perseus software suite (v. 1.6.2.3) was used to filter out contaminants, reverse hits and 
protein groups, which were only identified by site. Only protein groups that were detected in 
at least two out of the three replicates in at least one condition were considered for the 
analysis.  
The filtered data was log normalized and missing values were imputed according to the 
normal distributed imputation algorithm implemented in the Perseus framework. Default 
values were used (width: 0.3; down shift: 1.8). To find the significantly regulated protein groups 
a volcano plot analysis was performed with a difference of s0 =0.1 and a false discovery rate 
(FDR) of 0.05. The results were exported for further enrichment analyses performed on the 
reactome platform (www.reactome.org). 
3.2.17. Statystical analyses 
Except for the proteomics data, all statistical analyses were performed with GraphPad 
Prism 8. Analyses of paired measurements (time course, dose-response curve) between two 
groups were performed using the Sidak’s multiple comparisons test.   Analyses of paired 
measurements between three or more groups were performed using the Turkey’s multiple 
comparison test. Unpaired analyses were performed pairwise using the Mann-Whitney test. 
 
3.3. Materials 
3.3.1. Antibodies 
The following primary antibodies were used for western blot: Beclin1 (1:1000, Cell Signaling, 
#3495), ATG12 (1:1000, Cell Signaling, #2010), LC3B-II/I (1:1000, Cell Signaling, #2775), FLAG 
(1:7000, Rockland, 600-401-383), FKBP51 (1:1000, Bethyl, A301-430A), AKT (1:1000, Cell 
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Signaling, #4691), pAKT (Ser473 1:1000, Cell Signaling, #4058 and #9275), Actin (1:5000, Santa 
Cruz Biotechnology, sc-1616), GAPDH (1:8000, Millipore CB1001), TRIM16 (1:1’000, Bethyl 
A301-160A), IL1B (1:50, Cell Signalling, #12242), Cathepsin D (for Mouse) (1:50, Abcam, 
ABCAAB6313-100), SNAP29 (1:1000, Sigma, SAB1408650), SNAP23 (1:1000, Sigma, 
SAB2102251), STX3 (1:1000, Sigma, SAB2701366), STX4 (1:1000, Cell Signalling. #2400), GAL8 
(1:1’000, Santa Cruz, sc-28254), GAL3 (1:1’000, Santa Cruz, sc-32790), SEC22B (1:1000, Abcam, 
ab181076) 
3.3.2. Plasmids 
FKBP51-FLAG as described in Wochnik et al. 2004. 
The following expression vectors were purchased from Promega: NUP155-pFN21A, 
#FHC01121, SNCA-pFN21A #FHC02635, FKBP5-pFN21A #FHC02776, GAPDH-pFN21A 
#FHC02698, MEF2D-pFN21A #FHC00981, Halotaq-pFN21AB8354 #FHC02776, pFN21A HaloTag 
CMV Flexi Vector #9PIG282.  
GFP-Sec22b and Trim16-FLAG were kind gifts by Dr. Vojo Deretic (University of New Mexico).  
HT-FKBP51 isoform 2 expressing plasmid was generated by enzymatic cloning of the coding 
sequence (ENST00000542713.1) into the pFN21A HaloTag CMV Flexi Vector. 
FKBP51 CRISPR/ Cas9 KO  Plasmid (h), Santa Cruz #sc-401560; pSpCas9 BB-2A-Puro (PX459). 
V2.0 vector containing Atg5-targeting gRNA (Atg5 [house mouse] CRISPR gRNA 2: 
TATCCCCTTTAGAATATATC) purchased from GenScript. 
3.3.3. RT-qPCR primers 
FKBP5 transcripts 1-3 (Exon 11-12), IDT Hs.PT.58.813038: 
forward primer: AAAAGGCCAAGGAGCACAAC 
reverse primer: TTGAGGAGGGGCCGAGTTC 
FKBP5 (all transcripts Exon 5-6), IDT Hs.PT.58.20523859  
forward primer: GAACCATTTGTCTTTAGTCTTGGC    
reverse primer: CGAGGGAATTTTAGGGAGACTG  
 FKBP5 variant 4 (Exon 8-10b), IDT Hs.PT.58.26844122: 
forward primer: GAGAAGACCACGACATTCCA 
reverse primer: AGCCTGCTCCAATTTTTCTTTG 
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YWHAZ (Exon 9-10), IDT Hs.PT.58.4154200: 
forward primer: GTCATACAAAGACAGCACGCTA 
reverse primer: CCTTCTCCTGCTTCAGCTTC 
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4. Results 
 
4.1. Stress enhances chaperone-mediated autophagy via FKBP51 
Target-proteins of chaperone-mediated autophagy (CMA) are identified through a specific 
sequence by HSC70, and transported directly to the lysosome surface (Chiang et al., 1989). 
Here, the assembly of the lysosome-associated membrane protein type 2A (LAMP2A) into a 
multimeric complex translocates the substrate protein into the lysosome lumen where it is 
degraded by proteases (Bandyopadhyay et al., 2008; Cuervo and Dice, 1996). GFAP and EF1A 
modulate the complex assembly dynamics of LAMP2A (Bandyopadhyay et al., 2010). CMA is 
regulated by AKT that inhibits the translocation complex assembly through phosphorylation of 
GFAP. AKT, in turn, is inhibited by the phosphatase PHLPP or activated by mTORC2. With regard 
to the discovered role of FKBP51 on scaffolding AKT and PHLPP (Pei et al., 2009), a possible 
regulatory function of FKBP51 in CMA was hypothesized. Furthermore, since FKBP51 is 
activated by GR, the impact of GR-mediated stress as enhancer of CMA was investigated. 
 
4.1.1. Stress enhances degradation of known CMA targets 
Baseline activity of CMA is very low, but is enhanced in the presence of cellular stressors 
(hypoxia, starvation, oxidative stress). First, I investigated whether GR activation could trigger 
CMA. For this purpose, the synthetic GR agonist Dex was used in the neuroblastoma cell line 
SH-SY5Y. To monitor CMA activity, the degradation of known CMA targets was determined. 
Pulse-chase assays of the well-established CMA targets MEF2D (Yang et al., 2009), GAPDH 
(Aniento et al., 1993) and SNCA (Cuervo et al., 2004) were performed. As control, the long living 
protein NUP155 (Toyama et al., 2013) was analyzed under the same conditions. Furthermore, 
to control for CMA-mediated degradation only, the essential CMA regulator LAMP2A was 
knocked down (KD) via siRNA 48 hours prior to the experiment. In parallel, cells were 
transfected with scramble siRNA as control group. Fluorophore detection on western blot 
membrane revealed an increased degradation of all three analyzed CMA targets in response to 
Dex treatment in the control samples (transfected with scramble siRNA). However, knock down 
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of LAMP2A (KD) eliminated the effect of Dex on protein degradation. No differences between 
the two KD conditions (vehicle and Dex) and the vehicle control could be observed (fig.1 a, b, 
c). The negative control protein NUP155 remained unaffected by both Dex treatment and 
LAMP2A KD, confirming the validity of the experiment (fig. 1 d). 
 
 
 
Figure 1 – Effect of stress on degradation of known CMA targets. Fluorophore quantifications of 
western blots of samples from WT and LAMP2A KD SH-SY5Y cells, transfected with HT-plasmids, pulsed 
with a fluorophore and chased for 2, 4, 8, and 16 hours, during which time cells were treated with 100 
nM Dex or vehicle. HT-plasmids were expressing a) MEF2D, b) SNCA, c) GAPDH and d) NUP155. *P < 
0.05; **P < 0.01; ***P< 0.001. Tukey’s multiple comparison test. * refers to ctr veh vs. ctr Dex; # refers 
to ctr Dex vs. KD veh; $ refers to ctr Dex vs. KD Dex. Not indicated comparisons were not significant. 
 
4.1.2. FKBP51 mediates the effect of stress on CMA 
The pulse-chase experiments (fig. 1) revealed that GR activation enhances CMA-dependent 
degradation. At next, it was tested whether FKBP51 plays a role in mediating this effect. For 
this purpose, a FKBP51 KO SH-SY5Y cell line was generated via CRIPSR-Cas9. WT or FKBP51 KO 
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cells underwent treatment with Dex or vehicle followed by pulse-chase experiments with the 
known CMA target proteins (fig. 2), as described above. The results confirmed a stimulatory 
effect of Dex on the degradation of the CMA targets MEF2D, SNCA and GAPDH in WT cells. 
Interestingly, lack of FKBP51 resulted in the loss of the effect of Dex on target protein 
degradation, analogously as seen for the LAMP2A KD condition (fig. 2 a, b, c). The negative 
control NUP155 remained unaffected both by Dex and loss of FKBP51 (fig. 2 d). 
 
Figure 2 – Effect of stress on degradation of known CMA targets. Fluorophore quantifications of 
western blots of samples from WT and FKBP51 KO SH-SY5Y cells, transfected with HT-plasmids, pulsed 
with a fluorophore and chased for 2, 4, 8, and 16 hours, during which time cells were treated with 100 
nM Dex or vehicle. HT-plasmids were expressing a) MEF2D, b) SNCA, c) GAPDH and d) NUP155. *P < 
0.05; **P < 0.01. Tukey’s multiple comparison test. * refers to WT veh vs. WT Dex; # refers to WT Dex 
vs. KO veh; $ refers to WT Dex vs. KO Dex. Not indicated comparisons were not significant. 
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4.1.3. FKBP51 scaffolds lysosomal AKT and PHLPP 
These findings, indicating that FKBP51 plays an important role in CMA-dependent protein 
degradation, raised the question whether the hypothesis holds true that FKBP51 mediates AKT 
(de-) phosphorylation, crucial for proper CMA function. 
To test this hypothesis, lysosomes were purified from WT and FKBP51 KO SH-SY5Y cells that 
were cultured in serum-deprived medium for 72 hours in order to enhance CMA. Lysosome 
purification was determined by western blot quantifications of the main subcellular markers 
(fig. 3 a-c). A clear enrichment for lysosomal marker LAMP2A was obtained in the lysosomal 
fraction (Lys) compared to the whole cell lysate (WCL). In line with that, a distinctively 
decreased signal of the nuclear marker histone H3 was observed in the lysosomal fraction 
compared to the whole cell lysate, while the mitochondrial marker apoptosis-inducing factor 
(AIF) appeared unchanged, suggesting a mild mitochondrial contamination in the lysosomal 
fraction. The main CMA players were analyzed in the lysosomal fraction and compared between 
WT and FKBP51 KO (fig. 3 d). Interestingly, even though total AKT is increased in the absence 
of FKBP51, its phosphorylation levels (pAKT) are decreased compared to WT. In addition, levels 
of PHLPP are slightly decreased in the lysosomal fraction lacking FKBP51. This is in line with the 
hypothesized scaffolding role of FKBP51. Furthermore, Rapamycin-insensitive companion of 
mTOR (RICTOR), a protein associated with mTOR and only present in lysosomes capable to 
perform CMA (Arias et al., 2015), was interestingly found at lower levels in lysosomes of FKBP51 
KO samples. 
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Figure 3 – Validation of lysosome extraction. Western blots of lysosome extracts (Lys) and whole 
cell lysates (WCL) from WT and FKBP51 KO SH-SY5Y cells cultured in serum-deprived medium for 72 
hours. a) Quantification of lysosomal marker LAMP2A. b) Quantification of nuclear marker histone H3. 
c) Quantification of mitochondrial marker AIF. Western blot of known and hypothesized CMA 
modulators (AKT, pAKT, FKBP51, RICTOR) and normalizing control actin. 
 
To further test the interactions underlying possible CMA mechanisms, a co-
immunoprecipitation (co-IP) of AKT was performed in lysosome extracts and inputs as control, 
and analyzed for the main interactors via western blot. Results confirmed an interaction 
between AKT, PHLPP and FKBP51 on lysosomes, and that this interaction is strictly dependent 
on FKBP51 (absent in FKBP51 KO) (fig. 4). 
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Figure 4 – AKT co-IP on lysosome extracts and whole cell lysates. Immunoprecipitation of AKT 
followed by Western blotting for AKT, PHLPP, FKBP51, in lysosome extracts (Lysosome IP) and whole 
cell lysates (WCL) of SH-SY5Y cells cultured in serum-deprived medium for 72 hours. 
 
4.1.4. Proteome wide effect of stress on CMA and identification of novel 
targets 
Having proven that stress (Dex) enhances CMA-dependent degradation of selected targets, 
and having clarified the underlying mechanism, a proteome-wide, endogenous effect of stress 
on CMA was explored. I performed a 6 hour stable isotope labeling by amino acids in cell culture 
(SILAC), during which cells were incubated with 5x concentrated heavy isotope lysines (Lys 8) 
that replaced the natural light isotope lysines (Lys0) in newly synthetyzed proteins (fig. 5). This 
allowed the selective identification of degraded proteins during a 6 hours frame, which is 
indicative for active CMA.  
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Figure 5 – Schematic representation of inversed pulsed SILAC. Natural light lysine isotope (Lys 0) 
is replaced by heavy lysine isotope (Lys8) added at a 5x concentration for 6 hours to the medium, 
competing with Lys 0 and causing its chsase. 
 
An 8 hour Dex treatment was used as a stressor and was applied two hours before the heavy 
isotope labelling period in order to activate the CMA machinery. To control for specific 
degradation through CMA, the experiment was performed in cells knocked down for LAMP2A 
(KD), the key regulator of CMA. For this purpose, SH-SY5Y cells were transfected with siRNA 
targeting LAMP2A or scramble siRNA, 48 hours prior to the experiment. Samples were 
processed and analyzed via mass spectrometry. For SILAC quantification of the analyzed 
peptides, only the light isotope signal was considered. This allowed to observe the protein 
degradation, excluding novel protein synthesis. 6826 proteins were detected, and, after 
filtering, 5653 proteins were left for analysis. Volcano plot analyses were performed pairwise 
comparing the samples as indicated in figure 6. A strong effect of Dex was visible in the WT 
group (WT veh vs. Dex), with 4865 differentially regulated proteins, the vast majority of which 
was significantly degraded upon Dex treatment compared to vehicle (4850 vs. 15) (fig. 6 a). This 
large effect disappeared in the absence of LAMP2A, suggesting that the Dex-induced protein 
degradation is mediated by CMA (fig. 6 b). In the KD group (KD veh vs. Dex) a trend could be 
observed. These results were confirmed by complementary comparisons of WT vs. KD in vehicle 
or Dex treated conditions. Again, a significant effect was only seen in the Dex-treated condition, 
with 4172 degraded proteins in WT cells, and only 9 in LAMP2A KD cells (fig. 6 c). This result 
confirmed that Dex triggers CMA-dependent protein degradation. Interestingly, no effect was 
observed in the vehicle treated condition, suggesting that Dex stimulation is essential to 
enhance CMA (fig. 6 d).  
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Figure 6 – Volcano plots of light isotope proteins detected via mass spectrometry analysis. a) 
Comparison between WT SH-SY5Y treated with vehicle or 100 nM Dex for 8 hours. b)  Comparison 
between FKBP51 KO SH-SY5Y treated with vehicle or 100 nM Dex for 8 hours. c) Comparison 
between 8-hour 100 nM Dex treated WT and FKBP51 SH-SY5Y cells. d) Comparison between 8-hour 
vehicle treated WT and FKBP51 SH-SY5Y cells. Significantly regulated proteins are represented in red. 
FDR = 0.01, s0 = 0.1 
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Given a slight discrepancy in number of regulated proteins by Dex (WT vehicle vs. Dex) and 
by Dex-triggered CMA (WT Dex vs. KD Dex), a comparison between the degraded proteins 
resulting from the two groups was performed. Results displayed in the Venn diagram show that 
more than 80% of the proteins are present in both lists, meaning that these 3898 proteins are 
degraded via CMA only in response to Dex (fig. 7).  
 
 
Figure 7 Venn diagram. Comparison between significantly regulated proteins by CMA under 100 nM 
Dex and vehicle (veh) conditions in SH-SY5Y resulting from volcano plots. 
 
A functional enrichment analysis (https://reactome.org/) was performed on the group of 
proteins downregulated by Dex via CMA (3898 proteins). Results showed that regulated 
proteins were enriched in a variety of different cellular functions (fig. 8). Enrichment in cell 
cycle, DNA repair, metabolism of RNA, organelle biogenesis and maintenance, and metabolism 
of proteins are very interesting considering that autophagy has the main function of regulating 
homeostasis via these mechanisms that are the most energy consuming within the cell. This 
finding indicates that not only cellular stressors, but also GR activation can induce selective 
protein degradation.
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Figure 8 – Functional enrichment analysis. Visual representation of gene onthology enrichment analysis performed with Reactome 
(https://reactome.org/). Reactome pathways are arranged in hierarchies. Each center is the root of one toplevel pathway. In yellow the 
significantly enriched pathways (scale bar on the right).
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Furthermore, many proteins have been found enriched in vesicle-mediated transport that 
includes pathways involved in neurotransmitter release, synapse formation and neuronal 
plasticity (fig. 9).  
 
 
Figure 9 – Visual representation of enriched pathways in vescicle-mediated transport. In yellow 
the pathways and reactions of vesicle-mediated transport in which input proteins are significantly 
enriched. Data generated with Reactome (https://reactome.org/). Scale bar on the right. 
 
To deeper investigate this function, enrichment of Dex-triggered, CMA-modulated proteins 
were analyzed in the neurotransmitter release cycle and a large amount of proteins was found 
to be significantly enriched in almost every reaction of the pathway (fig. 10). 
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Figure 10 – Visual representation of enriched pathways in neurotransmitter release cycle. In 
yellow the pathways and reactions in which input proteins are significantly enriched. Data generated 
with Reactome (https://reactome.org/). 
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Among the 3898 regulated proteins, one was of particular interest: FKBP51 (fig. 11). 
Surprisingly, FKBP51 resulted regulated by Dex-triggered CMA in a sort of negative feedback or 
self-regulating mechanism. Possible implications will be pondered in the discussion section. 
 
 
Figure 11 – FKBP51 regulation in mass spectrometry analysis. Graphical display of light isotope 
(Lys 0) intensity values of FKBP51 from mass spectrometry analysis. Error bars in SEM. 
 
Overall, the SILAC mass spectrometry analysis showed that Dex has a large degradation 
effect on an unexpectedly extensive fraction of the proteome and that most of this effect is 
mediated by CMA.  
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4.2. Stress enhances secretory autophagy in the neuroimmune system 
After having seen that FKBP51 mediates the stress effect in CMA via its interaction with AKT 
and PHLPP, the question that novel binding partners might mediate additional functions was 
raised. To investigate this hypothesis, novel FKBP51 interactors were searched. 
 
4.2.1. SEC22B links FKBP51 to secretory autophagy 
To find novel binding partners of FKBP51, results from an interactome mass spectrometry 
performed by collaborators were analyzed. The interactome analysis was performed via co-IPs 
using HEK cells transfected with FLAG-tagged FKBP51 or an empty FLAG-expressing vector as 
control. In this quantitative-free approach, only FKBP51-FLAG but not FLAG-control interactors 
were selected for further analysis. These stringent analysis parameters led on one hand to an 
overrepresentation of false negatives, but, on the other hand, ensured identification of direct, 
strong and verified FKBP51 interactors.  
A resulting list of 29 binding partners was analyzed using the Panther classification system 
(http://www.pantherdb.org/). Eight different functional protein classes were identified. Among 
the interacting proteins resulted the vesicle trafficking protein SEC22B (fig. 12).  
 
Figure 12 – FKBP51 interactors. Pie-chart representation of FKBP51 interactors identified by mass 
spectrometry and functional classification. 
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A study by Kimura and colleagues presented SEC22B as a key molecule in secretory 
autophagy (fig. 13) (Kimura et al. 2017). Having seen the regulatory role of FKBP51 in other 
autophagic pathways and its role in mediating stress response and restoring homeostasis, the 
interaction between FKBP51 and SEC22B appeared of particular interest. Therefore, further 
investigations were conducted on the interaction between FKBP51 and SEC22B with the 
hypothesis of a possible regulatory function of FKBP51 in secretory autophagy. 
 
 
Figure 13 – Schematic overview of the secretory autophagy pathway. Stress-induced lysosomal 
damage is recognized by galectins, which recruite TRIM16 to the lysosome membrane. TRIM16 binds 
the secretory autophagy cargo and transfers it to the lumen of LC3B-coated autophagosome, via 
SEC22B. SEC22B binds then the plasma membrane SNAREs SNAP23/29 and STX3/4, mediating the 
exocytosis of the autophagosome content. 
 
First, SEC22B and two other putative binding partners from the interactome experiment, 
RACK1 and UBC12, were validated via co-IP and western blot analyses in the SH-SY5Y cell line 
(fig. 14). Results confirmed the interaction of FKBP51 with all of them (fig. 14 a). For SEC22B, 
we further confirmed the interaction with FKBP51 via reciprocal IP (fig. 14 b).  
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Figure 14 – Validation of FKBP51 interactions with SEC22B, UBC12 and RACK1. a) 
Immunoprecipitation of the FLAG tag followed by western blotting for FKBP51, SEC22B, UBC12 and 
RACK1 in SH-SY5Y cells transfected with FLAG-tagged FKBP51 (FLAG-IP) and the input as control. b) 
Immunoprecipitation of the GFP tag followed by western blotting for SEC22B and FKBP51 in SH-SY5Y 
cells transfected with GFP-tagged SEC22B (GFP-IP) and the corresponding input as control. 
  
Since SEC22B is described to be a key regulator of secretory autophagy, we further examined 
the interaction of FKBP51 with other major players of this pathway: the secretory autophagy 
cargo IL1B, its receptor TRIM16, and the autophagosome marker LC3B (fig. 15). Neither IL1B 
nor LC3B could be identified as FKBP51 interactors by analyzing the co-immunoprecipitate, 
suggesting that FKBP51 is neither actively part of the transport of cargo proteins, nor it is 
directly involved in the decoration of autophagic vesicles by LC3B. For TRIM16, a faint band was 
detected in the eluate, and we confirmed this weak interaction with the inverse co-IP (fig. 15 
b).  
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Figure 15 – Identification of novel FKBP51 interactors involved in secretory autophagy. a) 
Immunoprecipitation of the FLAG tag followed by western blotting for FKBP51, TRIM16, LC3B and IL1B 
in SH-SY5Y cells transfected with FLAG-tagged FKBP51 (FLAG-IP) and the corresponding input as 
control. b) Immunoprecipitation of the FLAG tag followed by western blotting for TRIM16 and FKBP51 
in SH-SY5Y cells transfected with FLAG-tagged TRIM16 (FLAG-IP) and the corresponding input as 
control. 
 
To further examine the potential role in the secretion dynamic, we analyzed the effect of 
FKBP51 on the interaction between IL1B and its receptor TRIM16, and between TRIM16 and 
SEC22B. For this purpose we used the CRISPR-Cas 9-generated FKBP51 KO SH-SY5Y cell line. Co-
IP analyses revealed no difference of interaction in the presence and absence of FKBP51 for 
both interactions (fig. 16). 
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Figure 16 – Effect of FKBP51 on TRIM16-IL1B and TRIM16-SEC22B interactions. a) 
Immunoprecipitation of the FLAG tag followed by western blotting for IL1B and SEC22B in WT and 
FKBP51 KO SH-SY5Y cells transfected with FLAG-tagged TRIM16 (FLAG-IP) and the corresponding input 
as control. Additional western blotting for FKBP51 was performed in the input to confirm the genotype. 
b) Quantification of IL-1B and SEC22B bound to TRIM16 in WT or FKBP51 KO cells. Mann-Whitney test. 
ns= not significant. Error bars expressed in SEM. 
 
FKBP51 expression is enhanced by GR activation and previous studies showed that it 
mediates the effect of stress on different pathways and cellular functions. Thus, we investigated 
weather GR activation had an effect on the interactions between TRIM16 and IL1B or SEC22B 
by stimulating cells with 100 nM Dex or vehicle for four hours. Co-IP analyses showed that Dex 
did not affect the interaction between TRIM16 and SEC22B. However, quantifications revealed 
a suprising decrease of interaction between TRIM16 and the cargo IL1B (fig. 17). Possible 
reasons behind this observation are presented in the discussion part. 
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Figure 17 – Effect of dexamethasone on TRIM16-IL1B and TRIM16-SEC22B interactions. a) 
Immunoprecipitation of the FLAG tag followed by western blotting for TRIM16, IL1B and SEC22B in SH-
SY5Y cells transfected with FLAG-tagged TRIM16 (FLAG-IP) and treated with 100 nM dexamethasone 
or vehicle for 4 hours. Below the corresponding inputs as control. b) Quantification of IL-1B and SEC22B 
bound to TRIM16 in 4 hours vehicle- or 100 nM Dex-treated conditions. Mann-Whitney test; ns= not 
significant, *P < 0.05. Error bars expressed in SEM. 
 
4.2.2. FKBP51 scaffolds membrane fusion complex 
Considering that FKBP51 had no function in the cargo transportation, nor in the 
sequestration membrane assembly, a possible role in the fusion of vesicles to the plasma 
membrane was hypothesized. To assess this hypothesis, I first analyzed the association of 
FKBP51 to other secretory autophagy-related soluble N-ethylmaleimide-sensitive factor 
attachment protein receptors (SNAREs): the synaptosomal-associated proteins 23 and 29 
(SNAP23/29) and the syntaxins 3 and 4 (STX3/4). Via co-IP analyses, strong interactions with 
SNAP23 and SNAP29 was detected (fig. 18). These are two SNAREs shown to be fundamental 
for secretory autophagy (Kimura et al., 2017). A signal for STX3 was also detected, while a 
possible very weak interaction with STX4 could be observed (fig. 18). The weaker interaction 
could suggest a possible indirect interaction through SNAP23/29 or STX3.  
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Figure 18 – Interaction of FKBP51 with SNAREs. Immunoprecipitation of the FLAG tag followed by 
western blotting for FKBP51, SEC22B, SNAP23, SNAP29, STX3 AND STX4 in SH-SY5Y cells transfected 
with FLAG-tagged FKBP51 (FLAG-IP) and the corresponding input as control.  
 
Kimura and colleagues demonstrated that SEC22B interacts with STX3/4 and SNAP23/29 to 
form SNARE-fusion complexes (Kimura et al., 2017). Since I found that FKBP51 binds to all these 
SNAREs, I investigated whether it plays a role in the SNARE complexes assembly. For this 
purpose a co-IP of SEC22B in WT and FKBP51 KO cells was performed. Furthermore, knowing 
the stress-mediating effect of FKBP51 described previously, I investigated whether GR 
activation affects the SNARE complex assembly via FKBP51 by analyzing the interactions 
between SEC22B and SNAP23/29 or STX3/4 after stimulation with Dex or vehicle (fig. 19). 
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Figure 19 – Effect of FKBP51 and Dex on SNARE complex asembly. a) Immunoprecipitation of the 
GFP tag followed by western blotting for SEC22B, SNAP23, SNAP29, STX3 and STX4 in WT and FKBP51 
KO SH-SY5Y cells transfected with GFP-tagged SEC22B (GFP-IP) and the input as control. b) 
Quantifications of SNAP23, SNAP29, STX3 and STX4 bound to TRIM16, expressed as fold change over 
vehicle. c) Quantification of input FKBP51 of samples treated for 4 hours with vehicle or 100 nM Dex. 
Mann-Whitney test; ns= not significant, *P< 0.05. Error bars expressed in SEM. 
 
Western blot analyses of the co-IPs showed a strengthened interaction upon Dex stimulation 
in WT cells. Contrarily, the absence of FKBP51 caused a total impairment of interaction both in 
vehicle and Dex stimulated conditions, proving that GR activation enhances SNARE complex 
formation in an FKBP51-dependent manner (fig. 19). 
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4.2.3. Stress affects lysosomal integrity and triggers secretory autophagy 
Having confirmed that Dex affects the assembly of the complex underlying secretory 
autophagy via FKBP51, other mechanisms leading to secretion were further investigated. 
Kimura and colleagues showed that secretory autophagy is initiated when lysosomes lose their 
integrity (Kimura et al., 2017). Based on this phenomenon, lysosomal integrity was analyzed to 
investigate whether Dex triggers secretory autophagy via the same mechanism.  
Galectin-3 (GAL3) and galectin-8 (GAL8) are established markers of damaged 
endomembranes (Paz et al., 2010; Thurston et al., 2012). Thus, expression levels of these two 
markers were analyzed in response to Dex stimulation. Quantifications of western blot analyses 
showed a significant increase in GAL8 protein levels in response to Dex, and a trend in increase 
of GAL3, suggesting an enhanced lysosomal damage (fig. 20).  
 
Figure 20 Effect of Dex on GAL3/8 expression. Quantification of western blot analyses for GAL3 and 
GAL8 normalized on ACTIN from WT SH-SY5Y cells treated with 100nM Dex or vehicle for 4 hours. 
Mann-Whitney test; ns= not significant, *P < 0.05, error bars expressed in SEM. 
 
To further clarify the molecular mechanism possibly linking lysosomal damage and secretory 
autophagy, the interaction of GAL3/GAL8 and FKBP51 was tested via co-IP in response to Dex. 
Interestingly, GAL8 presented a strong interaction to FKBP51 after Dex stimulation, compared 
to basal levels, while GAL3 did not seem to directly interact with FKBP51 (fig. 20). Using a 
mutated, TPR domain-lacking form of FKBP51, a decrease in GAL8 binding could be seen, 
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suggesting that this interaction is at least partially mediated by the TPR domain, and, thus, by 
HSP90 (fig. 21). 
 
 
Figure 21 – Interaction of FKBP51 with GAL3/8. Immunoprecipitation of the FLAG tag followed by 
western blotting for GAL3 and GAL8 SH-SY5Y cells transfected with FLAG-tagged FKBP51 WT or FLAG-
tagged FKBP51 lacking the TPR domain (FLAG-IP) and the input as control. 
 
To directly assess lysosomal damage, a tandem fluorescent-tagged Galectin-3 (tfGal3) was 
used. It is a construct that monitors the pH in (damaged) lysosomes by expressing GFP and RFP. 
Both RFP and GFP are stable at a neutral pH, but GFP is rapidly degraded in the acidic 
environment of intact lysosomes, while RFP remains intact (Maejima et al. 2013) (fig. 22). 
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Figure 22 – Stucture and function of fluorescence-tagged Galectin-3 (tfGal3). a) Diagram of the 
structure of tfGal3 construct. b) Schematic representation of the fate of tfGal3 recruited to damaged 
lysosomes. (Figure adapted from Maejima et al., 2013) 
 
After transient transfection with tfGal3, cells were subjected to various treatments for four 
hours and washed off for different durations as shown in figure 23. Leu-Leu-O-Me (LLOMe) and 
bafilomycin (Baf) were used as positive validations of the assay, as described by Meajima and 
colleagues (Maejima et al. 2013). LLOMe is a lysosome damaging and inflammasome activating 
substance, while Baf is an inhibitor of the vacuolar ATPase that controls pH in the lysosome. 
Through this mechanism, Baf prevents the acidification of lysosomes (Yoshimori et al. 1991). 
Using fluorescence microscopy, RFP and GFP fluorescent puncta were counted and the 
percentage of GFP+ puncta over the total RFP+ puncta was calculated. As expected, a significant 
reduction in GFP+ puncta after LLOMe treatment was detected, indicating severe loss of 
lysosomal integrity. The assay could also be validated by Baf that reverted the effect of LLOMe 
(fig. 23 a). Interestingly, Dex caused a significant decrease in GFP+ puncta with higher 
concentrations (30 nM and 300 nM), particularly noticeable with the 24 hours wash off, 
indicating lysosomal damage (fig. 23 b). This effect could also be rescued by co-application of 
Baf (fig. 23 b). These results indicate that high concentrations of Dex induce lysosomal damage.  
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Figure 23 – Quantifications of lysosomal damage via tfGal3 assay. a) Quantification of GFP+ puncta 
expressed in percentage of total RFP+ puncta in SH-SY5Y cells transfected with tfGal3 construct and 
treated with 1 mM LLOMe for 3 hours, followed by 4 , 8 and 24 hours wash off, and with 1 mM LLOMe 
+ Baf for 3 hours followed by 24 hours wash off. b) Quantification of GFP+ puncta expressed in 
percentage of total RFP+ puncta in SH-SY5Y cells transfected with tfGal3 construct and treated with 3 
nM, 30 nM and 300 nM, each for 3 hours, followed by 4, 8 and 24 hours wash off and with 300nM Dex 
+ Baf for 3 hours followed by 24 hours wash off. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. 
Tukey’s multiple comparison test. * indicate comparisons to vehicle; # indicate comparisons to 
treatment + Baf.  
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4.2.4. Dex affects autophagy-dependent Il1b secretion via Fkbp51 
in microglia 
The evidences collected so far point to the direction that stress affects lysosomal integrity 
and modulates the assembly of membrane fusion complex via FKBP51 in SH-SY5Y cells. This 
proposed mechanism is of particular interest in a neuroimmune environment. In fact, several 
studies revealed how secretory autophagy plays an important role in the extracellular signaling 
of immune response (Cadwell et al., 2008; Ushio et al., 2011; Michaud et al., 2011; Deretic et 
al, 2013). Thus, interaction of Fkbp51 with proteins of the membrane fusion machinery was 
analyzed in a murine microglia cell line, SIM-A9, via co-IP. As observed in SH-SY5Y cells, Fkbp51 
was found to strongly interact with the SNAREs Sec22b, Snap23 and Snap29, while a weaker 
interactions were detected with Stx3 and Stx4 (fig. 24). 
 
 
Figure 24 – Interaction of FKBP51 with SNAREs. Immunoprecipitation of the FLAG tag followed by 
western blotting for Fkbp51, Sec22B, Snap23, Snap29, Stx3 AND Stx4 in SIM-A9 cells transfected with 
FLAG-tagged FKBP51 (FLAG-IP) and the corresponding input as control.  
 
To further analyze the functional role of Fkbp51 in the membrane fusion machinery, Il1b, a 
known cargo of secretory autophagy was analyzed via enzyme-linked Immunosorbent assay 
(ELISA). To validate the assay, cells were first treated with LLOMe, known to trigger Il1b 
secretion (Ito et al. 2015). ELISA quantifications revealed a large increase of Il1b already after 4 
hours (fig. 25 a). Secreted Il1b was measured upon Dex treatment, as indicated in figure 25 b. 
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Interestingly, a strong increase of Il1b levels could be observed with 30 nM and 300 nM of Dex 
stimulation(fig. 25 b), the same concentrations that resulted causing lysosomal damage in SH-
SY5Y cells. This result evidenced that Dex, analogously to LLOMe, induces Il1b secretion in 
microglia. To assess whether the underlying mechanism is autophagy-, i. e. secretory 
autophagy-, dependent, an Atg5 KO SIM-A9 cell line was generated via CRISPR-Cas9. Atg5 is an 
essential regulator in secretory autophagy (Kimura et al. 2017), and loss of this protein 
ultimately leads to an impairment of this unconventional mechanism of protein secretion. The 
ELISA experiment was repeated in a Atg5 KO line and results showed a drastic reduction of 
secreted Il1b levels in Atg5 KO cells, compared to WT, upon Dex treatment (fig. 25 c), 
demonstrating that the Dex effect on secretory autophagy is tightly linked to Atg5-mediated 
signaling. Given that Fkbp51 plays a central role in SNARE complex assembly, the effect of 
Fkbp51 overexpression was examined. SIM-A9 cells were transfected with an Fkbp51-
expressing plasmid or control vector. After 24 hours, media were changed and 24 hours later 
media containing secreted proteins were collected and analyzed via ELISA.  Overexpression of 
Fkbp51 resulted in a significantly increased secretion of Il1b compared to control (fig. 25 d). 
This result confirms that Fkbp51 mediates the effect of stress on Il1b secretion.  
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Figure 25 – Quantification of IL1B via ELISA assy. Il1b from supernatants was measured via ELISA 
after SIM-A9 cells were treated as follow a) LLOMe for 4, 8 and 24 hours or vehicle for 24 hours. b) 
3nM, 30nM and 300nM or vehicle for 4 hours. c) 300nM Dex or vehicle for 4 hours in WT and Atg5 KO 
SIM-A9 cells. d) transfected with FKBP51 expressing plasmid or control vector. *P < 0.05; ***P< 0.001; 
****P< 0.0001. Tukey’s multiple comparison test was used for a, b and c; Mann-Whitney test was used 
for d. Significances in c are referred to comparison of Dex 300nM with each of the other conditions. 
Error bars expressed in SEM. 
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To control that the release of Il1b was due to active secretion and not unspecific leakage, 
amounts of lactate dehydrogenase (LDH) were measured in the medium of SIMA9-cells. LDH is 
a soluble cytosolic enzyme present in most eukaryotic cells, which is released into the culture 
medium upon damage of the plasma membrane. In line with data previously described by 
Kimura and colleagues (Kimura et al. 2017), levels of LDH were significantly increased in culture 
medium of SIM-A9 cells upon LLOMe treatment (fig. 26 a). Conversely, despite a visible trend, 
both Dex and overexpression of FKBP51, did not result in a significant release of LDH compared 
to controls (fig. 26 b, c). These results suggest that the enhanced release of Il1b described 
previously is due to an active mechanism rather than an unspecific cytotoxic effect. 
 
Figure 26 Quantification of secreted lactate dehydrogenase (LDH). LDH from supernatants was 
measured after SIM-A9 cells were treated as follow a) LLOMe or vehicle for 4 hours b) 3 nM, 30 nM 
and 300 nM Dex or vehicle for 4 hours. c) transfected with FKBP51 expressing plasmid or control vector. 
ns = not significant, *P < 0.01; Mann-Whitney test for Dex treatment and Tukey’s multiple comparison 
test for LLOMe treatment and FKBP51 overexpression. Significances are referred to comparisons with 
vehicle or control vector. Error bars expressed in SEM. 
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4.2.5. Proteome-wide effect of Dex on secretory autophagy 
 The data obtained so far give rise to the conclusion that the molecular machinery necessary 
for secretory autophagy is present in microglia cells. Furthermore, GR activation causes an 
Fkbp51-dependent increase of Il1b secretion. To assess a global effect of stress on secretory 
autophagy, and to detect possible novel cargo proteins, a secretome wide analysis was 
performed. 
A sophisticated approach, based on the method established by Eichelbaum and colleagues 
(Eichelbaum et al. 2012), was used to identify secreted proteins in a proteome-wide manner.  
Newly synthesized proteins were metabolically labeled for 12 hours and enriched to avoid 
abundant fetal bovine serum (FBS) proteins contained in the medium to be included in the 
secretome. To ensure that secretion of the analyzed proteins was autophagy dependent, 
microglial Atg5 KO cells were used. SIM-A9 WT or Atg5 KO were treated with Dex or vehicle for 
6 hours. Culture media were collected, from which secreted proteins were enriched and 
analyzed by mass spectrometry. The resulting secretome consisted of 862 detected proteins 
that were filtered, leaving 710 proteins for analysis. Volcano plot analyses were first performed 
comparing pairwise the four groups (fig 27 a, b, c, d). Unexpectedly, only two proteins resulted 
significantly regulated by Dex in WT cells and no protein was significantly regulated by Dex in 
Atg5 KO cells. Despite this result, a trend of increased proteins in the vehicle-treated sample 
was clearly visible in the WT condition. This modest but evident effect disappeared in the 
absence of Atg5 suggesting that there is a slight effect of Dex on secretory autophagy. 
Interestingly, a much greater effect was observed when comparing WT and Atg5 KO conditions. 
In both vehicle and Dex treated samples, a large number of proteins was significantly decreased 
in the absence of Atg5 (499 and 560 respectively) (fig. 27 c, d).  
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Figure 27 – Volcano plots of SIM-A9 secretome. a) Comparison between supernatants from WT 
SIM-A9 cells treated with 100 nM Dex or vehicle for 6 hours. b)  Comparison between supernatants 
from Atg5 KO SIM-A9 cells treated with 100 nM Dex or vehicle for 6 hours. c) Comparison between 
supernatant from 6 hours 100 nM Dex treated WT and Atg5 KO SIM-A9 cells. d) Comparison between 
supernatants from 6 hours vehicle treated WT and Atg5 KO SIM-A9 cells. Significant proteins are 
represented in red. FDR = 0.01, s0 = 0.1 
 
R e s u l t s  | 64 
 
 
Unexpectedly, these results suggest that, secretory autophagy is highly active even under 
basal conditions, although Dex appears to have an enhancing effect (61 proteins more secreted 
than under basal condition). To explore the differences in secreted proteins under basal and 
Dex stimulated conditions, proteins that were modulated by Atg5 in vehicle and Dex treated 
samples were compared (fig. 28). Results displayed in the Venn diagram showed that the 
secretion of 79 proteins was increased specifically in response to Dex. 
 
Figure 28 – Venn diagram of Atg5-dependent differentially secreted proteins. Comparison 
between significantly regulated proteins by CMA under 100 nM Dex and vehicle conditions in SH-SY5Y. 
 
A gene onthology enrichment analysis was performed on the “Dex-specific” protein group. 
Interestingly, results showed that the most prominent fraction of proteins was enriched in the 
immune system-related signalling (fig. 29).  
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Figure 29 – Gene onthology enrichment analysis. a) Visual representation of gene onthology 
enrichment analysis performed with Reactome (https://reactome.org/). Reactome pathways are 
arranged in hierarchies. Each center is the root of one toplevel pathway. In yellow the significantly 
enriched pathways (scale bar on the right). b) List of enriched pathways. Immune-related pathways 
are framed in orange. 
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4.2.6. Acute stress triggers Fkbp51-dependent secretion of Il-1b and Ctsd 
in vivo 
Given the results obtained in vitro, an in vivo analysis of the stress effect on hippocampal 
cellular secretion was conducted. In vivo hippocampal microdyalisis was performed while 
animals were subjected to foot-shock. This procedure was performed with WT and Fkbp51 
KO mice. Microdyalisate fractions were collected at baseline (three fractions), during 
footshock (FS; one fraction) and after footshock (post-FS; two fractions). As an established 
cargo of secretory autophagy, and in consistency with the previous experiments, Il1b was 
analyzed in the microdialysate fractions. Additionally, cathepsin d (Ctsd), another secretory 
autophagy cargo, described by Kimura and colleagues (Kimura et al., 2017), was measured.  
Dialysate fractions were analyzed via capillary electrophoresis and subsequent UV-
linking (Wes, ProteinSimple). Results revealed an increase in Il1b and Ctsd levels after 
footshock, which is in line with the in vitro data described previously (fig. 30 a, b). This 
increase was strongly diminished in the Fkbp51 KO animals (fig. 30 a, b), indicating that 
stress-induced secretion of Il1b and Ctsd is mediated by Fkbp51. To assess that secretion 
was dependent on the autophagic machinery, microdyalises were performed in animals 
treated with the autophagy inhibitor MRT 68921, an Ulk1-inhibitor confirmed to pass the 
blood brain barrier. Saline was applied to the control group. A significant increase in both 
Il1b and Ctsd was determined in the vehicle group after footshock (fig. 30 c, d). This 
enhancement was strongly impaired in mice treated with the autophagy inhibitor (AI; fig. 
30 c, d). These data corroborated and reinforced the in vitro findings showing that, not only 
Dex, but also in vivo stress had a strong effect on autophagy-dependent secretion of Il1b 
and Ctsd. 
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Figure 30 – Effect of stress on autophagy-dependent hippocampal secretion of Il1b and Ctsd. 
ProteinSimple quantifications of a) Il1b and b) Ctsd derived from in vivo hippocampal microdyalises 
of WT and Fkbp51 KO mice. ProteinSimple quantifications of c) Il1b and d) Ctsd derived from in 
vivo hippocampal microdyalises of vehicle and autophagy inhibitor MRT 68921 i.p. injected mice. 
*P < 0.05, **P < 0.01. Sidak’s multiple comparison test. # and $ refer to time x genotype/treatment 
and time only factors respectively resulting from two-way ANOVA analyses. Error bars expressed 
in SEM. 
 
4.2.7. Secretory autophagy as drug target 
The obtained results reveal that psychological stress enhances secretory autophagy, and, 
thus, possibly neuroinflammation. Given the central role of Fkbp51 in the regulation and 
mediation of the effect of stress on secretory autophagy, pharmacological targeting of this 
protein was tested. For this purpose, the microglia cell line SIM-A9 was treated with the 
Fkbp51 ligand, SAFit1 or vehicle as control. In addition, cells were treated with Dex or 
vehicle for four hours. Il1b secreted in the media was analyzed via ELISA. Quantifications 
indicated that SAFit1 treatments impaired the Dex-induced Il1b secretion (fig. 31).  
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Figure 31 – Quantification of IL1B via ELISA assy. Il1b from supernatants was measured via ELISA 
after SIM-A9 cells were treated with veicle, SAFit, 100nM Dex and 300nM Dex + SAFit for 4 hours. 
***P< 0.001; ****P< 0.0001. Tukey’s multiple comparison test. Not displayed comparisons were 
not significant. Error bars expressed in SEM. 
 
These results not only confirm that Fkbp51 is essential to mediate the effect of Dex on 
secretory autophagy, but also that Fkbp51 could be a potential target for anti-inflammatory 
therapy. 
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4.3. Characterization of FKBP51 isoforms and functions 
The presented results, in accordance to the literature, highlight the large variety of 
cellular pathways in which FKBP51 is implicated and unravel the vastness of stress effect. 
Nevertheless, to date, very few studies have focused on the two isoforms of FKBP51 and 
their potentially different roles in the regulation of cellular functions. To fill this gap, I 
characterized FKBP5/51 splicing variants and the resulting isoforms. 
 
4.3.1. Expression dynamics of FKBP5 splicing variants in response to 
dexamethasone 
In order to characterize the different transcriptional variants and protein isoforms of 
FKBP51, their expression levels were first determined via real time quantitative polymerase 
chain reaction (RT-qPCR), using material from HeLa cells (fig. 32).  
                                          
Figure 32 – RT-qPCR of FKBP51 variants at baseline. RT-qPCR quantification of FKBP51 variants 
expressed as percentage of the housekeeper YWHAZ in HeLa cells. 
 
Results evidenced the absence of variants 2 and 3. Low but measurable levels of variant 
4 could be detected. The highest signal was detected by using probes spanning all FKBP5-
variants. This indicates that large part of this signal derives from variant 1 expression. These 
results are in line with online expression data (https://gtexportal.org).  
At next, expression dynamics of the splicing variants were analyzed in response to Dex. 
For this purpose HeLa cells were exposed to 100 nM Dex or vehicle for 2, 4, 6, 12 and 24 
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hours, and transcription levels of the different variants were analyzed via RT-qPCR (fig. 33 
a). Due to the lack of sequence unicity for variant 1, probes spanning variants 1, 2 and 3 
were used. Considering the absence of variants 2 and 3, the observed signal was assumed 
to correspond to variant 1 and will be referred to as variant 1 from here on.  
 
Figure 33 Expression dynamic of FKBP51 variants in response to Dex a) RT-qPCR quantification 
of FKBP51 variants, expressed as fold induction of Dex-treated over vehicle-treated, normalized on 
the housekeeper YWHAZ, of HeLa cells treated with 100nM Dex or vehicle for 24 hours. b) Linear 
regression of b. *P < 0.05 ***P < 0.001, ****P < 0.0001. Sidak’s multiple comparisons test. # and 
$ refer to time by condition and time only factor respectively of two-way ANOVA test. Significance 
of the comparison between the linear regression lines resulted from the linear regression analysis. 
 
The expression of both variant 1 and 4 was significantly increased in response to Dex 
across time. Interestingly, despite having lower expression at basal levels, variant 4 showed 
an increased response ratio over vehicle compared to variant 1 at early time points 
(significantly different at 2, 4 and 6 hours). Furthermore variant 4 showed a more 
immediate response to Dex than variant 1: variant 4 levels were significantly increased 
already after two hours of treatment while at the same time point variant 1 was still 
expressed at baseline levels. This faster dynamic could be observed throughout the 
measured time course. In fact, variant 4 showed an early peak at 4 hours and a following 
steady slope, while variant 1 expression was reflected in a slowly increasing curve up to 24 
hours. This difference is visually summarized with the linear regression lines that show a 
significant difference (fig. 33 b).  
 
4.3.2. Degradation of FKBP51 protein isoforms 
With regard to the findings observed in expression dynamics, proteins half-lives were 
determined at next. To assess the protein stability of the two FKBP51 isoforms, a pulse-
chase approach was used. HeLa cells were transfected with Halo-Tag (HT) plasmids coding 
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for either isoform 1 or 2. 24 hours later, cells were tagged with a cell permeable 
halogenated fluorophore 16, 8, 4 and 2 hours before harvesting. After harvesting the cells, 
proteins were extracted and subjected to western blot, and fluorescence intensity was 
measured on nitrocellulose membrane (fig. 34). Results indicated that isoform 2 was 
degraded faster with a half-live of four hours, while isoform 1 reached 50% of degradation 
only after 8 hours (fig. 34). 
 
Figure 34 – Degradation dynamics of FKBP51 isoform 1 and 2 Pulse chase assay of FKBP51 
isoform 1 and 2 of HeLa cells transfected with HT-isoform 1 or HT-isoform 2, pulsed with a 
fluorophore and chased for 2, 4, 8, and 16 hours. Quantifications were made from western blots. 
*P < 0.05. Sidak’s multiple comparisons test. 
 
Together with the expression dynamics, these data suggest a faster turnover of variant 
4/isoform 2 compared to variant 1/isoform1. 
 
4.3.3. Intracellular localization of isoform 1 and 2 
The scarcity of information available regarding FKBP51 intracellular localization appears 
to be highly dependent on antibodies used for detection (https://www.proteinatlas.org), 
while no information is available for the different isoforms. To gain more insight about the 
cellular role of FKBP51, intracellular localization of both isoforms was analyzed. Due to the 
lack of commercially available or specific enough antibodies for FKBP51 isoform 2, and to 
avoid potential artifacts deriving from immunocytochemical processing, HeLa cells were 
transfected with plasmids coding for GFP-tagged isoforms 1 or 2. A plasmid expressing only 
GFP was used as control. Cells were live imaged with epifluorescent microscopy 24 hours 
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after transfection (fig. 34). Resulting images showed ubiquitous signal from the control-
transfected cells. Isoform 1 presented a cytoplasmic accumulation, while isoform 2 showed 
a distinct subnuclear (probably nucleolar) localization. 
 
Figure 34 – Subcellular localization of FKBP51 isoform 1 and 2. Epifluorescent and bright field 
imaging of HeLa cells transfected with GFP-tagged FKBP51 isoform 1, GFP-tagged FKBP51 isoform 
2, or GFP-control vector 24 hours prior to imaging. 
 
In addition to the imaging approach, to determine cellular localization the transfected 
cells were harvested and subjected to subcellular fractionation to separate nuclear from 
cytoplasmic proteins. Fractionation was validated via western blot analyses and GFP signal 
was quantified in both nuclear and cytoplasmic fractions (fig 35 a, b). Results showed clean 
fraction separation and quantification analyses confirmed a large enrichment of isoform 2 
in the nucleus. Surprisingly isoform 1 appeared slightly more enriched in the nucleus after 
fractionation. 
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Figure 35 – Isoform 1 and 2 localization visualized by subcellular fractionation a) Subcellular 
fractionation of HeLa cells transfected with GFP-tagged FKBP51 isoform 1, GFP-tagged isoform 2 
and GFP-vector as control followed by western blotting for GFP, GAPDH (cytoplasmic marker) and 
H3 (nuclear marker) in the cytoplasmic and nuclear fraction. b) Quantifications of western blots 
from a) normalized on GAPDH and H3 for cytoplasmic and nuclear fractions respectively. 
 
 
4.3.4. Differential regulation of cellular pathways 
The aim of the following part was to characterize the functional aspects of the two 
isoforms of FKBP51.  
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4.3.4.1. GR inhibition 
In the previous parts I described that both FKBP5 variants were responsive to Dex-
dependent expression, which impacts the GR-FKBP51 interplay and can define a novel level 
of GR-regulation through FKBP51. In the following part I investigated whether the two 
isoforms possess a negative feedback function on GR. 
Activity of the different isoforms on GR was assessed via GRE-driven reporter gene 
assays. HeLa cells were co-transfected with MMTV-Luc, a GRE-driven luciferase, and with a 
plasmid coding for either isoform 1, isoform 2 or an empty vector as a control. Cells were 
then treated with increasing concentrations of Dex, and luminescence was measured 48 
hours after transfection (fig. 36). Cells overexpressing isoform 1 showed a significantly lower 
dose-response curve compared to cells overexpressing isoform 2 and controls, which, in 
turn, were perfectly overlapping. Isoform 1 desensitizes GR: higher concentrations of Dex 
were required to evoke GR activation. 
 
Figure 36 – Isoform 1- and 2-dependent effect of Dex on GRE activation. GRE-driven reporter 
gene assay performed in HeLa cells transfected with FKBP51 isoform 1 (ect iso1), FKBP51 isoform 
2 (ect iso2) or an empty vector (ctr vector), treated with 0.1 nM, 0.3 nM, 1 nM, 3 nM, 10 nM, 30 
nM, 100 nM or vehicle for 4 hours. *P < 0.05, ***P < 0.001, ****P < 0.0001. Turkey’s multiple 
comparisons test.  * and $ indicate comparisons between ctr vector and ect iso 1 and between ect 
iso1 and ect iso 2 respectively. Error bars expressed in SEM. 
 
 
To confirm these findings, the reporter-gene assay was repeated with FKBP51 KO cells. 
CRISPR-Cas 9 approach was used to selectively ablate isoform 1 (iso 1 KO) or both isoforms 
(full KO) in HeLa cells using specific guide RNAs (fig.37).  
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Figure 37 – Schematic visualization of gRNA targeting variants 1-3 or variants 1-4 of FKBP51. 
Target loci of gRNA targeting variants 1-3 and all variants used to generate HeLa FKBP51 full KO 
and isoform 1 KO respectively. 
 
WT, full KO and isoform 1 KO cells were transfected with MMTV-Luc and, after 48 hours, 
treated with increasing concentrations of Dex. After 4 hours, luminescence intensity was 
measured (fig. 38). The resulting dose-response curve of the full KO and isoform 1-KO were 
overlapping and both showed increased activity compared to WT. This result suggests that 
the lack of isoform 1 allows lower concentration of Dex to activate GR, and that isoform 2 
alone (isoform 1 KO) is not able to rescue this effect. 
 
Figure 38 – Isoform 1- and 2-dependent effect of Dex on GRE activation. GRE-driven reporter 
gene assay performed in HeLa cells WT, lacking both isoforms of FKBP51 (full KO) or lacking isoform 
1 only (iso 1 KO), treated with 0.1 nM, 0.3 nM, 1 nM, 3 nM, 10 nM, 30 nM, 100 nM or vehicle for 4 
hours. *P < 0.05, **P < 0.01, ****P < 0.0001. Turkey’s multiple comparisons test.  * and # express 
comparison of WT with full KO and iso 1 KO respectively; $ refers to comparison between full KO 
and iso 1 KO. Error bars expressed in SEM. 
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Taken together, the results of both reporter-gene assays indicate that isoform 1 alone, 
and not isoform 2, has an inhibitory function on GR. 
 
4.3.4.2. Macroautophagy regulation 
As known from the literature, and seen in the previous results, another very important 
protein regulated by FKBP51 is AKT. As discussed throughout this thesis, autophagy is a 
major regulator of cellular homeostasis, and as demonstrated previously, it is responsive to 
GCs via FKBP51 (previous results for secretory autophagy and CMA; Gassen et al. 2014 for 
macroautophagy). In the following part, the role of the two isoforms of FKBP51 was 
analyzed on macroutophagy.  
Upstream regulation of autophagy is tightly controlled by the kinase AKT. AKT (activated 
when phosphorylated) inactivates the autophagy initiator Beclin 1 via phosphorylation. In 
turn, AKT can be inactivated through dephosphorylation by the phosphatase PHLPP. This 
process is mediated by FKBP51.  
Isoform 1, 2 or an empty vector as control was overexpressed in HeLa cells, and different 
actors and downstream effectors of the macroautophagy pathway were analyzed via 
western blot. Quantifications of the phosphorylated AKT showed that overexpression of 
both isoform 1 and 2 led to a decreased phosphorylation of AKT (pAKT) compared to control 
(fig. 39).  
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Figure 39 – Effect of FKBP51 isoforms on AKT phosphorylation. a) Quantification of western 
blots analyses for pAKT normalized on total AKT from HeLa cells transfected with FKBP51 isoform 
1, FKBP51 isoform 2 or an empty vector. *P < 0.05. Mann-Whitney test. * indicates comparisons 
with ctr vector. Error bars expressed in SEM 
 
Decreased pAKT leads to an enhanced autophagy. Therefore, the following autophagic 
markers were analyzed: Beclin1, upstream regulator of autophagy and modulated directly 
by AKT, ATG12, involved in expansion of autophagososmes, and LC3BII (lipidated form of 
LC3B-I), marker of autolysosome formation. 
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Figure 40 – Effect of FKBP51 isoforms on autophagy markers. Quantification of western blots 
analyses for b) Beclin1, c) ATG12 and c) LC3BII/I ratio from HeLa cells transfected with FKBP51 
isoform 1, FKBP51 isoform 2 or an empty vector. *P < 0.05. Mann-Whitney test. * and # indicate 
comparisons with ctr vector and isoform 2 respectively. Error bars expressed in SEM. 
 
 
Overexpression of isoform 1 led to an increase of Beclin1 and ATG12. Interestingly, 
overexpression of isoform 1 did not lead to an increase of LC3BII (normalized on LC3BI). 
Furthermore, overexpression of isoform 2 did not affect levels of Beclin1, but lead to 
increased ATG12 and LC3BII/I.  
 
4.3.4.3. NFAT regulation 
Data presented so far indicate the importance of the effect of stress on the immune 
function. A possible link via the regulation of secretory autophagy by FKBP51 was revealed. 
Another way to regulate the immune response through FKBP51, though, is the modulation 
of Calcineurin-NFAT signalling (T.-K. Li et al. 2002). FKBP51 isoform 1 overexpression leads 
to an increased phosphorylation and thus to inhibition of NFAT. The role of isoform 2 on 
this pathway was here analyzed. 
For this purpose, the immortalized human T lymphocyte cell line Jurkat was used. 
Plasmids coding for isoforms 1 or 2 of FKBP51 were overexpressed and pNFAT levels were 
analyzed via western blot. As expected, quantifications revealed an increase of pNFAT when 
overexpressing isoform 1. Conversely, overexpression of isoform 2 did not affect pNFAT 
levels compared to control (fig. 41). 
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Figure 41 – Effect of FKBP51 isoforms on NFAT phosphorylation. Quantification of western blots 
analyses from HeLa cells transfected with FKBP51 isoform 1, FKBP51 isoform 2 or an empty vector, 
for pNFAT normalized on total NFAT. *P < 0.05. Mann-Whitney test. * and # indicate comparisons 
with ctr vector and isoform 2 respectively. Error bars expressed in SEM. 
 
4.3.4.4.  Regulation of DNA methylation 
DNA methylation is a genome-wide mechanism to regulate gene expression that can be 
environmentally modulated. Gassen and colleagues found that FKBP51 modulates DNA 
methytransferase 1 (DNMT1) activity via phosphorylation in response to antidepressants, 
affecting genome-wide methylation levels.  
To test the effect of the two FKBP51 isoforms on the phosphorylation (i. e. activation) 
levels of DNMT1 (pDNMT1), isoforms 1 or 2 of FKBP51 were overexpressed in HeLa cells. 
pDNMT1 was detected via western blot analysis and normalized to total DNMT1 (fig. 42). 
Quantifications indicated a large reduction of pDNMT1 in the presence of isoform 1 
overexpression. Contrarily overexpression of isoform 2 did not affect DNMT1 
phosphorylation compared to control. 
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Figure 42 – Effect of FKBP51 isoforms on NFAT phosphorylation. Quantification of western blots 
analyses from HeLa cells transfected with FKBP51 isoform 1, FKBP51 isoform 2 or an empty vector, 
for pDNMT1 normalized on total DNMT. *P < 0.05. Mann-Whitney test. * and # indicate 
comparisons with ctr vector and isoform 2 respectively. Error bars expressed in SEM. 
  
Overall, these data revealed that the two FKBP51 isoforms can have equivalent or 
opposite effects. The reasons behind this and the possible implications will be examined in 
the discussion part. 
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5. Discussion 
 
Autophagy is one of the most evolutionarily conserved cellular mechanisms. It is a 
catabolic process that can be activated through cellular stressors like starvation or oxidative 
stress. The cell self-digests its components in order to maintain the correct homeostasis of 
proteins, protein complexes and organelles. Interestingly, Gassen and colleagues 
established a molecular link between stress signaling via the GR and autophagy activation 
(Gassen et al., 2014). In this study, the stress responsive protein FKBP51 is presented as a 
scaffolder and key driver of a regulatory protein heterocomplex essential for autophagy 
initiation. The possible link between stress signaling and homeostasis regulation mediated 
by FKBP51 motivated me to further explore the effect of stress on two more specialized 
types of autophagy: chaperone-mediated autophagy, a protein-selective lytic process, and 
secretory autophagy, a more recently described mechanism that leads to the secretion of 
cytosolic material. Interestingly, and in line with the study described above, my results could 
show that GR activation does enhance both analyzed pathways. This underlines the 
important role stress may play on cellular and protein homeostasis (proteostasis). My 
proposed model is in line with recent theories delineating that disbalanced proteostasis 
might underlie chronic mental illnesses (Bradshaw and Korth, 2018). These unraveled 
mechanisms also highlighted the need to further characterize FKBP51. For this reason I 
investigated the expression and degradation dynamics of FKBP5/51’s splicing variants and 
protein isoforms, their intracellular localization and the differential roles they play in specific 
cellular pathways. The results revealed different kinetics, localization and domain-
dependent roles of the two isoforms, highlighting the importance of a deeper investigation 
of FKBP51 to fully understand the molecular mechanisms underlying the regulation of stress 
response. 
 
5.1. Effect of stress on Chaperone Mediated Autophagy (CMA) 
CMA is characterized by its selectivity. Target proteins are identified by HSC70 through 
a specific amino acid sequence and are transported directly to the lysosome surface (Chiang 
et al., 1989). Here, the assembly of the multimeric complex, regulated by LAMP2A, leads to 
the translocation of the substrate protein into the lysosome lumen where it is degraded by 
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proteases. The activity of CMA is tightly controlled by AKT, which inhibits the translocation 
complex assembly via phosphorylation of GFAP. In turn, AKT is inhibited or activated 
respectively by PHLPP and mTORC2, which can be considered as the upstream regulators 
of CMA. CMA is constitutively active at low levels, but is enhanced upon cellular stress 
(hypoxia, starvation, oxidative stress). In this study, I could demonstrate that stress 
mediated by GR-signaling is able to enhance CMA, analogously to cellular stress. The first 
results obtained with pulse-chase experiments, show a great effect of the synthetic GR 
agonist Dex on the degradation of known CMA targets, which resulted to be both CMA 
(LAMP2A)- and FKBP51-dependent (fig. 1). A more attenuated effect of the LAMP2A KD (no 
significance between ctr Dex and KD Dex for MEF2D) might rely on the fact that the 
elimination of LAMP2A was not complete and low levels of CMA activity might have 
persisted. The co-IP experiments performed on extracted lysosomes could confirm the 
underlying hypothesized mechanism that presents FKBP51 as a scaffolder for the 
interaction between PHLPP and AKT, promoting CMA activation. A minor mitochondrial 
contamination in the lysosomal extracts, represented by the AIF signal, could have been a 
possible interference in the analysis of the results, but the enhanced AKT signal in the 
lysosomal fraction, indicates that this enrichment can only be attributed to lysosomes. 
Furthermore, FKBP51 has been described to localize in the mitochondria where it plays an 
anti-oxidative role in complex with GR and PKA, but no evidence suggest an involvement of 
AKT. This indicates that the AKT-FKBP51 interaction, observed with the co-IP, can be 
specifically attributed to lysosomes. 
The successive analysis of the proteome-wide effect of GR activation on CMA-mediated 
protein degradation, revealed a surprisingly large degradation in response to stress. Almost 
70% of the detected proteins resulted degraded in response to Dex via CMA. Yet, it needs 
to be considered that the observed results describe the degradation effect omitting novel 
synthesis. This approach reveals proteins that are regulated via CMA, but it overestimates 
the actual net effect. Additional examinations of the CMA net effect (including the protein 
synthesis and observing the total balance), might indicate more precise implications of this 
regulatory mechanism. Possibly, within this detected pool of proteins, subsets of targets are 
degraded in dependence of the cell type or the stress stimulus. This hypothesis is supported 
by the example of SNCA, a protein regulated via CMA and whose aberrant degradation 
specifically in the brain, is implicated in Parkinson´s disease (Cuervo et al., 2004; Ho et al., 
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2019). Furthermore, stress-triggered regulation of CMA may not only unravel molecular 
mechanisms contributing to psychiatric or neurodegenerative disorders, but also constitute 
a possible target for novel medications. In fact, therapeutic activation of CMA has been 
considered as a possible treatment for Parkinson´s disease (Ho et al., 2019). Further 
functional enrichment analyses, performed on differentially regulated proteins, indicate a 
high enrichment of Dex-induced, CMA-regulated proteins in synaptic plasticity and 
neurotransmitter release signaling (fig. 9 and 10). These findings suggest a direct link 
between proteostasis, neuronal plasticity and synapse formation. Hakim and colleagues 
highlighted the importance of proteostasis in synaptic functions focusing on ubiquitin-
proteasome system (UPS)-mediated degradation of synaptic proteins. Their findings 
implicate that the main driver for synaptic proteostasis must be a mechanism other than 
the UPS (Hakim et al., 2016). I suggest that such mechanism is, at least in part, CMA. For my 
study, the neuroblastoma SH-SY5Y cell line was chosen in order to have a background that 
was as neuronal as possible, with the advantage of an easy-to handle, human cell line. In 
fact, most of the studies conducted so far on CMA have used rodent models. For further 
investigations, human induced pluripotent stem cell (hiPSC)-derived neurons could better 
highlight human neuron-specific proteins regulated by CMA. In addition, investigation of 
the synaptic proteome, complemented by functional analysis methods such as 
electrophysiology, could unveil the suggested role of CMA in synaptic proteostasis and 
plasticity. 
 
5.2. Stress affects secretory autophagy 
Supporting the model that describes GR activation as a trigger of proteostasis regulation, 
the results of the here presented study indicate that stress enhances secretory autophagy. 
Via an unbiased proteomic approach, SEC22B, the main regulator of secretory autophagy 
(Kimura et al., 2017), was identified as novel binding partner of FKBP51 (fig. 12). In vitro 
experiments confirmed that FKBP51 is a component and essential player of the assembly of 
the SNARE complex regulating the membrane fusion in secretory autophagy. Furthermore, 
Dex treatment led to enhanced interactions within the SNARE complex (fig. 19). Even 
though FKBP51 was shown not to affect the interaction between TRIM16 and the cargo 
protein IL1B, and between TRIM16 and SEC22B, the Dex treatment resulted in a lower 
interaction between TRIM16 and IL1B. An explanation for this is an increased flow of 
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secretory autophagy, triggered by Dex, for which IL1B is secreted at higher rates, causing a 
detachment between IL1B and its receptor TRIM16.  
Several studies suggest that macro- and secretory autophagy are triggered by lysosomal 
damage (Chauhan et al., 2016; Jia et al., 2018, 2019; Kimura et al., 2017; Maejima et al., 
2013). Thus, lysosomal integrity and the related expression of galectins were tested. 
Galectins are cytosolic lectins, able to recognize lysosomal membrane damage by binding 
to luminal β-galactosides from glycoconjugates exposed to the cytosol upon membrane 
damage. GAL3 and GAL8 have been found to recruit autophagic receptors on the damaged 
site and transport the cargo to autophagosomes (Chauhan et al., 2016; Thurston et al., 
2012). Using western blot analyses, I have found increased levels of GAL8 upon Dex 
treatment, which indicate increased lysosomal damage. Furthermore, co-IP experiments 
indicated that GAL8 interacts with FKBP51 and that this interaction is HSP90-dependent (fig. 
21). These results suggest that FKBP51 is recruited on damaged lysosomes and bridges the 
fusion to autophagosomes via SEC22B. Experiments using the tfGal3 construct to monitor 
damaged lysosomes confirmed that Dex stimulation indeed leads to decreased lysosomal 
integrity (fig. 23). In line with these results, ELISA assays performed in murine microglia cells, 
analyzing the known cargo Il1b, showed that Dex treatment enhances Il1b secretion via 
secretory autophagy (fig. 25). Taken together these results indicate that Dex triggers 
secretory autophagy via FKBP51. To better understand the global impact of secretory 
autophagy activation, the secretome wide effect of Dex was tested with the use of Atg5 KO 
cells. Atg5 is an autophagy–related protein shown to be essential for secretory autophagy 
(Kimura et al., 2017). Comparisons between WT and Atg5 KO samples showed a surprisingly 
high amount of proteins secreted via secretory autophagy even at basal levels (70% of the 
total detected proteins), although Dex stimulation increased this regulation (78% of the 
total detected proteins). Surprisingly, Dex treatment did not significantly affect protein 
secretion in WT cells, although a trend was detected. Interestingly, though, within the Atg5 
KO samples, the trend seen in the WT upon Dex stimulation disappeared. This suggests that 
the observed trend is indeed resulting from the Dex treatment. In fact by blocking secretory 
autophagy, Dex does not have any effect on protein secretion anymore. A plausible reason 
underlying the lack of significance might be a high basal activity. A technical aspect that 
might explain the high secretory autophagy levels is that the metabolic labeling used for 
protein enrichment can stress the cells if applied for a long time. I incubated the cells for 12 
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hours in order to label as many proteins as possible without having evident toxic effects. 
This could be a limiting factor, without which the differentially regulated proteins by 
secretory autophagy would have been more, and the Dex effect in the WT group would 
have probably been stronger. Furthermore, mass spectrometry is a potent tool for wide-
scale analyses; nevertheless it is less sensitive than single protein analyses methods such as 
ELISA or western blot. In fact, Il1b was not detected in the secretome analysis, indicating 
insufficient sensitivity of the method. This limitation, however, suggests an underestimation 
of the observed effect, strengthening these results.  
 
5.3. Secretory autophagy as mechanism underlying the interplay 
between stress and immune response  
The microglia cell line SIM-A9 was chosen because several studies revealed that 
secretory autophagy plays an important role in the extracellular signaling of immune 
response. Microglia cells constitute between 5% and 10% of the total brain cells and are the 
main macrophages of the central nervous system (Aguzzi et al., 2013). Furthermore, the 
interplay between stress response and immune activation is of particular interest. 
Classically, stress has a suppressive effect on the immune system and it is known that this 
inhibitory effect is carried out by the HPA axis via GCs. Activation of GR can directly impair 
pro-inflammatory transcription by interacting with transcription factors NF-κB and AP-1 
(Ratman et al., 2013), or, via GRE binding, enhancing or repressing transcription of anti- or 
pro-inflammatory genes respectively (Muzikar et al., 2009). Activation of the HPA axis, 
however, can also activate the immune system, enhancing the secretion of cytokines that 
promote different types of inflammatory responses (Takahashi et al., 2018). In fact, low 
doses of GCs can enhance the production of the macrophage migration inhibitory factor 
(MIF), a pro-inflammatory cytokine (Calandra et al., 1995). Moreover, the activation of 
inflammatory activity can be triggered by stress even in absence of infectious pathogens, 
via the HPA axis, as observed in case of depression (Audet et al., 2014). It has been shown 
that stressful experiences can increase levels of pro-inflammatory cytokines in the brain 
(Steptoe et al., 2007) either locally, secreted by activated microglia (Liu et al., 2014; Wohleb 
et al., 2015), or via systemic transport (Banks, 2006). To explain these opposite roles of GCs, 
Frank and colleagues (Frank et al., 2013) proposed a differential action of GCs depending 
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on timing and intensity of the stressor. During stress, when GC levels are increased, the 
resulting effect is anti-inflammatory, whereas during the recovery phase, when GC are 
decreasing to basal levels, there is a sensitization of the immune response. This model is 
supported by the observation of immune priming in microglia consequently to GC 
treatment (Frank et al., 2011). Along this line, further studies showed sensitization of the 
HPA axis and the immune response to subsequent LPS challenge greatly inducing central 
and peripheral pro-inflammatory activators after chronic and acute social disruptive stress 
(Gibb et al., 2013). This priming of the immune system by stress has also been suggested to 
mediate side effects such as allodynia (Loram et al., 2011) and drug abuse (Frank et al., 
2011), and is proposed to be involved in major depression disorder (MDD) (Liu et al., 2014). 
It was therefore particularly interesting to find the Dex-triggered, autophagy-secreted 
proteins, resulting from the mass spectrometry analysis, to be highly enriched in the 
immune system pathways (fig. 29). These findings may unravel a global molecular 
mechanism underlying the link between stress and neuroimmune response. In particular, 
the effect of in vivo stress on hippocampal Il1b secretion highly supports this model. Further 
analyses analyzing inflammatory markers in the murine brains after stress exposure, would 
illustrate the hypothesized pathological effect of stress on neuroinflammation. Additionally, 
the treatment with the FKBP51 ligand SAFit not only reversed the effect of Dex, confirming 
FKBP51´s central role in stress-induced secretory autophagy, but also revealed itself as a 
promising, novel way to target neuroinflammation. The link between stress and immune 
system, however, is bidirectional. The immune system can, in fact, have a behavioral effect 
by modulating the HPA axis. Pro-inflammatory cytokines such as IL1B, interleukin 6 (IL6), 
and tumor necrosis factor α (TNFA) have been found to interfere directly with GR, inhibiting 
its negative feedback regulation on the HPA axis (Pace et al., 2007; Van Bogaert et al., 2010). 
Moreover, cytokines can also directly enhance the activity of the HPA axis by amplifying its 
feed forward signaling. IL1B and IL6 have been shown to amplify the stress effect on CRH 
and ACTH secretion respectively (Chover-Gonzalez et al., 1993; Mehet et al., 2012). 
Additionally, another study found that inhibition of IL1B receptor, decreases ACTH release 
in response to restraint stress, corroborating the proposition that cytokines may amplify 
stress-induced HPA axis activation (Gądek-Michalska et al., 2011). Therefore, not only 
psychological stress can lead to an increased immune activation, but also chronic 
inflammation can modify the HPA axis response and lead to psychiatric disorders 
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((Berkenbosch et al., 1987; Linthorst et al., 1994; Angeli et al., 1999). This suggests the 
existence of a possible positive feedback resulting from GR activation, via secretory 
autophagy. Further in vivo analysis investigating this circling effect might reveal additional 
information on this mechanism. In addition, analyses of inflammation markers in animal 
models or human post mortem tissues can deepen the understanding of downstream 
effects and clinical implications. 
 
5.4. Effect of stress on proteostasis 
As mentioned before, autophagy is one of the most evolutionarily conserved cellular 
responses to starvation. The cell self-digests its own components to provide nutrients in 
order to maintain essential cellular functions and to eliminate superfluous or damaged 
organelles, misfolded proteins, and invading micro-organisms (Levine and Kroemer, 2008). 
Here, I show that these energy-conservation and quality control processes can also be 
triggered by GR-mediated stress. A previous study showed that macroautophagy is 
triggered by GR activation (Gassen et al., 2014). Together with the current results showing 
the same effect on CMA and secretory autophagy, it can be implied that environmental 
stress has an effect on global proteostasis regulated by different autophagic pathways. As 
a transcription factor, GR has been in the focus for its role in transcriptional regulation. 
Here, however, an additional level of GR regulation was revealed: the activation of protein 
degradation and secretion. This dual function of GR might underlie a very sophisticated 
regulation process. Acute stress activates a complex machinery that triggers an appropriate 
response, and, in turn, holds the organism in its equilibrium state. My findings indicate that 
this regulatory mechanism is more complex than thought so far, and that proteostasis might 
be a central part of it. Enhanced transcription and translation of genes involved in stress 
response is counter-regulated by an increase in autophagy levels also triggered by GR 
activation itself. Numerous studies show that an inappropriate response to (chronic) stress 
can lead to psychiatric disorders for the development of which, a proportion of risk factors 
involve non-genetic causes. Bradshaw and colleagues summarize some evidences that lead 
to the hypothesis that aberrant proteostasis might underlie chronic mental illnesses in 
complement to the genetic causes (Bradshaw and Korth, 2018). My results are in line with 
this hypothesis: impaired stress response can lead to impaired proteostatic regulation, 
which could be complementary to or even resulting from genetic causes underlying 
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psychiatric disorders. In fact, an example of how a specific genotype could be strictly related 
to impaired stress response and homeostasis is FKBP5. The haplotype rs1360780 is 
associated with FKBP5’s expression levels and constitutes a risk factor for the development 
of different psychiatric disorders. Considering the role of FKBP51 in the different autophagic 
pathways, it appears clear that the FKBP5 genotype can directly influence proteostasis. This 
constitutes a possible mechanism underlying the link between genetics and psychiatric 
disorders.  
A very interesting and central aspect of the GR-induced regulatory mechanism is the 
dynamic between lytic and secretory autophagy, and the effect of stress on it. In fact, acute 
stress leads to activation of macroautophagy, CMA and secretory autophagy. Experiments 
with the tfGal3 construct, however, demonstrate that Dex stimulation induces lysosomal 
damage. Prolonged GR activation, as occurs in chronic stress and different psychiatric 
disorders, may cause a switch from lytic to secretory autophagy. In fact, damaged lysosomes 
are not functional for macroautophagy and CMA anymore, and are discarded via secretory 
autophagy. This process leads not only to an accumulation of cellular waste, because all the 
autophagic burden is derailed on the overloaded secretory autophagy, but also leads to a 
lack of recycling, since secretory autophagy only discards the collected material. As a 
consequence, protein aggregates and disrupted organelles accumulate in the cell, and 
building blocks for novel synthesis are at scarce causing a strong energetic imbalance. This 
imbalance, or impaired homeostasis, can lead to the development of several 
neurodegenerative and psychiatric disorders (fig. III). 
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Figure III – Schematic representation of homeostasis in response to stress. Impaired levels of 
stress response and FKBP51 (either too low or to high) lead to impaired homeostasis and, 
consequently, to a diseased state.  
 
5.5. Self-regulation of FKBP51 
FKBP51 is the common denominator of the effect of stress on all these different levels. 
Interestingly, within the homeostatic regulation of GR, FKBP51 appears to have an 
autonomous self-regulating mechanism that counterbalances the effect of stress on this 
versatile protein on multiple levels. At the genetic level, FKBP51 indirectly regulates its own 
expression by inhibiting its activator GR (Davies et al., 2002). Furthermore, Klengel and 
colleagues unraveled the mechanism underlying the link between FKBP5 polymorphisms 
and epigenetic regulation via DNA methylation (Klengel et al., 2013). In addition, FKBP51 
was found to regulate DNMT1, one of the main DNA methyltrasferases, and, thus, indirectly 
regulate its own expression via epigenetic modifications (Gassen et al., 2015a). Another 
epigenetic mechanism through which FKBP5 is regulated is via miRNA (Sun et al., 2018; Volk 
et al., 2016). Studies showed that FKBP51 interacts with and regulates argonaute proteins 
which together with miRNAs form the RNA-induced silencing complex (RISC) responsible for 
RNA silencing (Martinez et al., 2013; Taipale et al., 2014). Therefore, FKBP51 can also 
indirectly modulate its post-transcriptional regulation by modulating miRNA activity. In a 
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recently published study we demonstrated that, in immune cells, FKBP5 expression can be 
regulated by NF-kB, which is known to be in turn enhanced by FKBP51, resulting in a positive 
feedback loop of FKBP5 expression (Zannas et al., 2019). With the current study, I gained 
evidence that FKBP51 can regulate itself also on an additional level, via CMA. In fact, Dex-
enhanced levels of FKBP51 elevate CMA activity of which FKBP51 itself is a target. 
Interestingly, genetic and epigenetic self-regulatory mechanisms of FKBP5/51 have all been 
linked to psychiatric or inflammatory disorders. These findings were collected from in vitro 
analyses performed in the neuroblastoma cell line SH-SY5Y, which allowed me to have a 
handy experimental approach (e.g. FKBP51 KO generation, SILAC labelling, good 
transfectability) and a neuronal-like background. However, to gain a better understanding 
of this regulatory mechanism, the use of more specific in vitro models, such as hiPSC-
derived neurons or more complex models like cerebral organoids would be preferable. In 
addition, behavioral experiments and post-mortem brain analyses would allow a translation 
from a mechanistic to a functional and clinical investigation. The self-regulatory mechanism 
of FKBP51 also increases the interest of using this protein as drug target.  
 
5.6. FKBP51 variants and isoforms: implications and future 
directions 
All evidences highlight a central role for FKBP51 in stress response and its implication in 
numerous stress-related disorders. Furthermore, its self-regulation within the GR negative 
feedback mechanism, suggests a fine-tuning function for FKBP51. To better examine this 
potential role, expression and degradation dynamics of FKBP51 isoforms and their 
differential functions in known molecular pathways were analyzed in HeLa cells. The first 
experiments revealed that only variants 1 and 4, coding for isoform 1 and 2 respectively, 
were detected and that variant 1 is expressed at much higher levels than variant 4 (fig. 32), 
which is in line with online expression data (https://gtexportal.org). Interestingly, upon Dex 
stimulation, variant 4 showed a much higher increase than variant 1, compared to basal 
levels (fig 33). Furthermore, measurement of the protein degradation kinetics, via pulse 
chase-assay, showed a shorter half-life for isoform 2 (4 hours) compared to isoform 1 (8 
hours) (fig. 34). The collected data suggest a different dynamic for the two different 
isoforms. In particular, isoform 2 appears to have a faster degradation rate, which might 
correspond to a more fine-tuning function. Furthermore, localization analyses showed a 
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strong nuclear (probably nucleolar) enrichment of isoform 2, while isoform 1 presented an 
equal distribution between cytoplasm and nucleus. This result not only suggests different 
roles for the two isoforms, but also indicates the existence of unknown functions of FKBP51 
in the nucleus. To shed light on possible novel functions of isoform 2, the impact of isoform 
1 and 2 onto known pathways was compared. The two isoforms were found to exert 
opposite regulatory effects on GR, NFAT and DNMT1 signaling (fig. 36, 38, 41, 42). 
Interestingly, the regulation of all these pathways depends on the interaction with HSP90. 
It is therefore not surprising that isoform 1 affects inhibition of GR and phosphorylation of 
NFAT and DNMT1, while isoform 2 does not have any effect on their function since it lacks 
the TPR domain responsible for the interaction with HSP90. On the other hand, pathways 
regulated via the interaction with AKT and PHLPP are modulated by both isoforms, since 
the interaction is dependent on the FK1 domain. The immediate consequence of FKBP51 
interaction to AKT and PHLPP is dephosphorylation of AKT. Interestingly, while AKT de-
phosphorylation is equally regulated by the two isoforms, downstream effects, such as 
increase of autophagy markers, are not (fig. 39, 40). This finding suggests the existence of 
an additional mechanism for which isoform 2 has a decreased effect on autophagy 
activation. Presumably, isoform 2 has a lower binding affinity for Beclin1. Interestingly, 
though, isoform 2 appears to have a stronger effect in later stages of the autophagic 
pathway (autophagosome expansion and autolysosome formation), suggesting an 
alternative pathway, or a faster activity of isoform 2 compared to isoform 1. Once again, 
these results suggest different functional roles for the two isoforms. Considering the 
different functions related to the different domains, it would be of particular interest to 
explore the functions related to the unique sequence of 46 aa of isoform 2. In silico analyses 
performed with the Expasy Prosite database (https://prosite.expasy.org/) revealed the 
presence of a putative nuclear localization signal (NLS) inside the unique sequence, which 
might underlie the observed nuclear localization of isoform 2. Additionally, clinical 
observational and correlational analyses in case control cohorts can be used to broaden the 
clinical understanding of the two isoforms. In our lab, expression levels of FKBP5 splicing 
variants (mRNA) and protein isoforms are being analyzed in post-mortem brain samples 
deriving from patients with schizophrenia, bipolar disorder, major depression disorder and 
healthy controls. Possible differential expression of FKBP51 variants in correlation with a 
diseased state would further clarify not only the splicing variant/isoform-specific function, 
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but also a possible specificity of the brain regions. However, these analyses remain 
observational and correlational. Complementary in vivo analyses would clarify the 
functional mechanisms. 
Another important aspect, for which a better understanding of FKBP51 isoforms and 
their roles are important, is to use FKBP51 as a drug target. Given its involvement in 
numerous diseases, FKBP51 has gained visibility as therapeutic target. So far, SAFit appears 
to be the only candidate able to selectively target FKBP51 over its closest homologue 
FKBP52 in an efficient way. It binds to the FK pocket within the FK1-domain, which means 
it can theoretically regulate both isoforms of FKBP51. Pharmacological modulation with 
SAFit in vivo led to decreased chronic pain and increased stress-coping behaviors (Balsevich 
et al., 2017; Maiarù et al., 2016), while in vitro treatment of neuroblastoma cells with SAFit 
caused a downregulation of the isoform 2-specific downstream target PD-L1. My current 
study shows a potential use of SAFit for stress-induced neuroinflammation. In vitro 
experiments showed, in fact, the reversing effect of SAFit in stress-induced secretory 
autophagy in microglia cells (fig. 31). FKBP51´s regulation of a large set of different 
molecular pathways, however, increases the chance of undesired side effects. A solution to 
this problem could be a more selective targeting of specific functions. This selectivity could 
be achieved by targeting a single FKBP51 isoform. Targeting the TPR domain would 
guarantee selectivity for isoform 1. This would mean to impair all molecular functions 
modulated via HSP90, first among all, GR inhibition. To selectively target isoform 2 could be 
of particular interest, given the observed faster response dynamic to stress. A deeper 
characterization of isoform 2, however, would be necessary. Furthermore, from a 
stereochemical and pharmacological point of view, designing a ligand for a 46 aa unique 
sequence to selectively target isoform 2 might be extremely challenging. As mentioned in 
the beginning of this doctoral thesis, FKBP51 provides a more dynamic phenotype with an 
enhanced response to stress but also a stronger response to anti-depressants. Impairing 
this mechanism could, therefore, lead to an inefficient alteration and undesired side effects. 
For this reason, targeting downstream players of selective pathways modulated by FKBP51 
could be an alternative option. 
As summarized in figure IV, this work presents FKBP51 in a central stage of a novel level 
of homeostasis regulation in response to stress. The majority of evidence was gained with 
in vitro analyses using cell lines, which offered the advantage of being a fast and 
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manipulable system. As a next step, in vivo or more complex and specific in vitro tools (e.g. 
hiPSC induced specific cell types or organoids), might offer a better milieu for further 
investigations of these pathways and functions. 
 
 
Figure IV – Schematic summary of the functions of FKBP51. Newly discovered role of FKBP51 in 
CMA and secretory autophagy. Mediation of AKT dephosphorylation and subsequent activation of 
macroautophagy by both FKBP51 isoforms (further clarifications regarding the extent of isoform 2 
on this pathway still needed). Regulation of DNA methylation via DNMT1 and activation of the 
NFAT –mediated immune response by FKBP51 isoform 1 (iso 1) only.  
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6. Acronyms and abbreviations 
 
3D Three-dimensional 
ACTH adrenocorticotropic hormone  
AGO Argonaute protein 
AIF Apoptosis-inducing factor 
AKT or PKB Protein kinase B  
AP-1 Activator protein 1 
AR Androgen receptor 
AS160 Akt substrate 160 
ATG protein autophagy-related protein 
BBB blood brain barrier  
BD Bipolar disorder 
ACN Acetonitrile 
C-terminal/ terminus Carboxyl terminal/ terminus 
CaN Calcineurin 
CBG corticosteroid binding globulin  
CDK4/5 Cyclin-dependent kinase 
ChIP chromatin immunoprecipitation experiments  
CMA Chaperone - mediated autophagy 
CNS Central nervous system 
CORT Cortisol/ corticosterone 
CRH corticotropin-releasing hormone  
CRHR1 corticotropin-releasing hormone receptor 1 
Cyp40 Cyclophilin 40 
Dex Dexamethasone 
DLC1/2 Deleted in Liver Cancer ½ 
DNA Deoxyribonucleic acid 
DNMT1 DNA-methyltransferase 1 
ELISA Enzyme-linked Immunosorbent Assay 
FA Formic acid 
FK1/2 FK506-binding (domain)  
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FKBP5/51/52 FK506-Binding Protein 5/51/52 
GAL3/8 Galectin 3/8 
GC Glucocorticoid 
GFAP Glial fibrillary acidic protein 
GR glucocorticoid receptor 
GRE Glucocorticoid Response Element 
gRNA Guide RNA 
GSK3b Glycogen synthase kinase 3 beta 
hiPSC human induced Pluripotent Stem Cells 
HPA hypothalamic pituitary adrenal  
HSC70 Heat shock cognate 70 
HSP90 Heat shock protein 90 
IkB NF-kB inhibitor 
IKK IκB kinase 
IL1B Interleukin-1 beta 
IL1B/2/6 Interleukin 1 beta/2/6 
IP Immunoprecipitation 
i.p. Intraperitoneal 
ISOC Store-operated calcium entry current  
JAK Janus kinase 
KD Knock down 
KO Knock out 
LAMP2A  Lysosome-associated membrane protein type 2A  
LE ligand efficiency 
LPS Lipopolysaccharide 
MC2-R melanocortin type 2 receptor  
MCM minichromosome maintenance  
MDD Major depressive disorder 
MIF  migration inhibitory factor  
miRNA micro RNA 
MR mineralocorticoid receptor 
mRNA messenger RNA 
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mTOR Mechanistic (or mammalian) target of rapamycin 
N-terminal/terminus Amino-terminal/terminus 
NFAT Nuclear factor of activated T-cells 
NF-kB Nuclear factor kappa-light-chain-enhancer of activated B-cells 
NLS Nuclear localization signal 
NUP155 Nuclear pore complex protein 
PHLPP PH domain and Leucine rich repeat Protein Phosphatases 
PKA protein kinase A 
PP5 Protein Phosphatase 5 
PPIase peptidylprolyl isomerase 
PR Progesterone receptor 
PTSD Post traumatic stress disorder 
PVN paraventricular nucleus 
RhoA Ras homolog family member A 
RISC RNA-induced silencing complex  
RNA Ribonucleic acid 
ROCK Rho-associated protein kinase 
RICTOR Rapamycin-insensitive companion of mTOR 
SAFit Selective Antagonist of FKBP51 by induced fit 
SEC22B SEC22 Homolog B, Vesicle Trafficking Protein 
siRNA small interfering RNA 
SNAP 23/29 Synaptosomal-associated protein 23/29 
SNARE soluble N-ethylmaleimide-sensitive-factor attachment receptor 
SNCA Alpha-synuclein 
SNP Single Nucleotide Polymorphism 
STAT Signal transducer and activator of transcription proteins 
STX3/4 Syntaxin 3/4 
TBP TATA box-binding protein 
TNFA Tumor necrosis factor alpha 
TPR tetratricopeptide repeat (motif) 
TRAF TNF receptor associated factors 
TRIM16 Tripartite motif-containing protein 16 
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TSS Transcription start site 
TSST Trier social stress test  
WCL Whole cell lysate 
WT Wild Type 
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